<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0801233067
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LINDYNETTE 0.075/0.03 mg Film-coated Tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ETHINYLESTRADIOL,GESTODENE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        0.03,0.075
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        21
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        18.4
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="GEDEON RICHTER PLC." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            GEDEON RICHTER PLC.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 1916]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            AJA PHARMACEUTICAL INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            AJA PHARMACEUTICAL INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        G03AA10 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Lindynette is a combined oral contraceptive pill (&lsquo;the Pill&rsquo;).&nbsp;<strong>You take it to stop you getting pregnant</strong>.</p><p>&nbsp;</p><p>This contraceptive contains two types of female sex hormones, oestrogen and progestogen.</p><p>These hormones stop you getting pregnant by working in three ways: by preventing an egg being released from your ovaries; by making the fluid (mucus) in your cervix thicker, which makes it more difficult for sperm to enter the womb; and by preventing the lining of your womb thickening enough for an egg to grow in it.</p><p>&nbsp;</p><p>Lindynette is a 21-day Pill &ndash; you take one each day for 21 days, followed by 7 days when you take no pills.</p><p>&nbsp;</p><p>Lindynette will not protect you against sexually transmitted infections, such as Chlamydia or HIV. Only condoms can help to do this.</p><p>&nbsp;</p><p style="text-align:justify"><strong>Lindynette needs to be taken as directed to prevent pregnancy</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>General Notes</strong></p><p>Before you start using Lindynette you should read the information on blood clots in section 2. It is particularly important to read the symptoms of a blood clot &ndash; see Section 2.3 &lsquo;Blood clots&rsquo;.</p><p>It&rsquo;s important that you understand the benefits and risks of taking the Pill before you start taking it, or when deciding whether to carry on taking it. Although the Pill is suitable for most healthy women it isn&rsquo;t suitable for everyone.</p><p>&nbsp;</p><p>-&nbsp;<strong>Tell your doctor&nbsp;</strong>if you have any of the illnesses or risk factors mentioned in this leaflet.</p><p>&nbsp;</p><p><strong>Before you start taking the Pill</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will ask about you and your family&rsquo;s medical problems, check your blood pressure and exclude the likelihood of you being pregnant. You may also need other checks, such as a breast examination, but only if these examinations are necessary for you, or if you have any special concerns.</p><p>&nbsp;</p><p><strong>While you&rsquo;re on the Pill</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp; You will need regular check-ups with your doctor or family planning nurse, usually when you need another prescription of the Pill.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; You should go for regular cervical smear tests.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Check your breasts and nipples every month for changes &ndash; tell your doctor if you can see or feel anything odd, such as lumps or dimpling of the skin.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; If you need a blood test tell your doctor that you are taking the Pill, because the Pill can affect the results of some tests.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; If you&rsquo;re going to have an operation, make sure your doctor knows about it. You may need to stop taking the Pill at least 4 weeks before the operation. This is to reduce the risk of a blood clot (see section 2.3). Your doctor will tell you when you can start taking the Pill again.</p><p>&nbsp;</p><p><strong>2-1&nbsp;&nbsp;&nbsp; When you should not use Lindynette</strong></p><p>You should not use Lindynette if you have any of the conditions listed below. If you do have any of the conditions listed below, you must tell your doctor. Your doctor will discuss with you what other form of birth control would be more appropriate.</p><p>&nbsp;</p><p><strong>Do not use Lindynette:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp; If you have (or have ever had) a blood clot in a blood vessel of your legs (deep vein thrombosis, DVT), your lungs (pulmonary embolus, PE) or other organs</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; If you know you have a disorder affecting your blood clotting &ndash; for instance, protein C deficiency, protein S deficiency, antithrombin-III deficiency, Factor V Leiden or antiphospholipid antibodies</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; If you need an operation or if you are off your feet for a long time (see section 2.3 &lsquo;Blood clots&rsquo;)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; If you have ever had a heart attack or stroke</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; If you have (or have ever had) angina pectoris (a condition that causes severe chest pain and may be a first sign of a heart attack) or transient ischaemic attack (TIA &ndash; temporary stroke symptoms)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; If you have any of the following diseases that may increase your risk of a clot in the arteries:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; severe diabetes with blood vessel damage</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; very high blood pressure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; a very high level of fat in the blood (cholesterol or triglycerides)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; a condition known as hyperhomocysteinaemia</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; If you have (or have ever had) a type of migraine called &lsquo;migraine with aura&rsquo;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; If you have or have ever had breast cancer</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; If you have ever had a severe liver disease, and you have been told by your doctor that your liver function test results are not yet back to normal</p><p>-&nbsp;&nbsp;&nbsp; &nbsp;If you have ever had liver tumours</p><p>-&nbsp; &nbsp;&nbsp;&nbsp;If you are allergic (hypersensitive) to any of the ingredients in Lindynette</p><p>&nbsp;</p><p>Do not use Lindynette if you have hepatitis C and are taking the medicinal products containing ombitasvir / paritaprevir / ritonavir and dasabuvir or glecaprevir / pibrentasvir (see also in section &lsquo;Taking other medicines&rsquo;)</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;<strong>Tell your doctor or family planning nurse&nbsp;</strong>if you have any medical problems or illnesses</p><p>&nbsp;</p><p><strong>2-2&nbsp;&nbsp;&nbsp; When to take special care with Lindynette</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>When should you contact your doctor?</p><p>&nbsp;</p><p><u>Seek urgent medical attention</u></p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; if you notice possible signs of a blood clot that may mean you are suffering from a blood clot in the leg (i.e. deep vein thrombosis), a blood clot in the lung (i.e. pulmonary embolism), a heart attack or a stroke (see &lsquo;Blood clots&rsquo; section below).</p><p>&nbsp;</p><p>For a description of the symptoms of these serious side effects please go to &lsquo;How to recognise a blood clot&rsquo;.</p><p><strong>&nbsp;</strong></p></td></tr></tbody></table><p>&nbsp;</p><p>Some of the conditions listed below can be made worse by taking the Pill. Or they may mean it is less suitable for you. You may still be able to take Lindynette but you need to take special care and have check-ups more often.</p><p>&nbsp;</p><p><strong>Tell your doctor if any of the following conditions apply to you.</strong></p><p>If the condition develops, or gets worse while you are using Lindynette, you should also tell your doctor.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; If you have Crohn&rsquo;s disease or ulcerative colitis (chronic inflammatory bowel disease)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; If you have systemic lupus erythematosus (SLE &ndash; a disease affecting your natural defence system)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; If you have haemolytic uraemic syndrome (HUS &ndash; a disorder of blood clotting causing failure of the kidneys)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; If you have sickle cell anaemia (an inherited disease of the red blood cells)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; If you have inflammation of the pancreas (pancreatitis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; If you have elevated levels of fat in the blood (hypertriglyceridaemia) or a positive family history for this condition. Hypertriglyceridaemia has been associated with an increased risk of developing pancreatitis (inflammation of the pancreas)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; If you need an operation, or you are off your feet for a long time (see in section 2.3 &lsquo;Blood clots&rsquo;)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; If you have just given birth you are at an increased risk of blood clots. You should ask your doctor how soon after delivery you can start taking Lindynette</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; If you have an inflammation in the veins under the skin (superficial thrombophlebitis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; If you have varicose veins</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; If you have diabetes</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; If you or your close family have ever had problems with your heart, or circulation such as high blood pressure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; If you or your close family have ever had problems with blood clotting</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; If you have the inherited disease called porphyria</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; If you are overweight (obese)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; If you have migraines</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; If you have any illness that worsened during pregnancy or previous use of the Pill (see section 4.2)</p><p>&nbsp;</p><p><strong>2-3&nbsp; &nbsp;&nbsp;Blood Clots</strong></p><p>Using a combined hormonal contraceptive such as Lindynette increases your risk of developing a blood clot compared with not using one. In rare cases a blood clot can block vessels and cause serious problems.</p><p>Blood clots can develop:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in veins (referred to as a &lsquo;venous thrombosis&rsquo;, &lsquo;venous thromboembolism&rsquo; or VTE),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in the arteries (referred to as an &lsquo;arterial thrombosis&rsquo;, &lsquo;arterial thromboembolism&rsquo; or ATE).</p><p>Recovery from blood clots is not always complete. Rarely, there may be serious lasting effects or, very rarely, they may be fatal.</p><p>&nbsp;</p><p><strong>It is important to remember that the overall risk of having a harmful blood clot due to Lindynette is small.</strong></p><p>&nbsp;</p><p><strong>HOW TO RECOGNISE A BLOOD CLOT</strong></p><p><u>Seek urgent medical attention&nbsp;</u>if you notice any of the following signs or symptoms.</p><table border="1" cellspacing="0" cellpadding="0" style="width:576px"><tbody><tr><td style="vertical-align:top"><p><strong>Are you experiencing any of these signs?</strong></p></td><td style="vertical-align:top"><p><strong>What might you be suffering from?</strong></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of one leg or along a vein in the leg or foot especially when accompanied by:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain or tenderness in the leg which may be felt only when standing or walking</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased warmth in the affected leg</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; change in colour of the skin on the leg e.g. turning pale, red or blue</p></td><td style="vertical-align:top"><p><strong>Deep vein thrombosis</strong></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp; sudden unexplained breathlessness or rapid breathing</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; sudden cough without an obvious cause, which may bring up blood</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; sharp chest pain which may increase with deep breathing</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; severe light headedness or dizziness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; rapid or irregular heartbeat</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; severe pain in your stomach</p><p>- If you are unsure, talk to a doctor as some of these symptoms such as coughing or being short of breath may be mistaken for a milder condition such as a respiratory tract infection (e.g. a &lsquo;common cold&rsquo;).</p><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Pulmonary embolism</strong></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Symptoms most commonly occur in one eye:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; immediate loss of vision or</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; painless blurring of vision which can progress to loss of vision</p><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Retinal vein thrombosis (blood clot in the eye)</strong></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp; chest pain, discomfort, pressure, heaviness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; sensation of squeezing or fullness in the chest, arm or below the breastbone</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; fullness, indigestion or choking feeling</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; upper body discomfort radiating to the back, jaw,&nbsp; throat, arm and stomach</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; sweating, nausea, vomiting or dizziness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; extreme weakness, anxiety, or shortness of breath</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; rapid or irregular heartbeats</p><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Heart attack</strong></p></td></tr><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp; sudden weakness or numbness of the face, arm or leg, especially on one side of the body</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; sudden confusion, trouble speaking or understanding</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; sudden trouble seeing in one or both eyes</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; sudden trouble walking, dizziness, loss of balance or coordination</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; sudden, severe or prolonged headache with no known cause</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; loss of consciousness or fainting with or without seizure</p><p>Sometimes the symptoms of stroke can be brief with an almost immediate and full recovery, but you should still seek urgent medical attention as you may be at risk of another stroke.</p></td><td style="vertical-align:top"><p><strong>Stroke&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp; swelling and slight blue discolouration of an extremity</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; severe pain in your stomach (acute abdomen)</p></td><td style="vertical-align:top"><p><strong>Blood clots blocking other blood vessels</strong></p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>See a doctor as soon as possible. Do not take any more Lindynette until your doctor says you can. Use another method of contraception, such as condoms, in the meantime.</strong></p><p>&nbsp;</p><p><strong>BLOOD CLOTS IN A VEIN</strong></p><p>&nbsp;</p><p><strong>What can happen if a blood clot forms in a vein?</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp; The use of combined hormonal contraceptives has been connected with an increase in the risk of blood clots in the vein (venous thrombosis). However, these side effects are rare. Most frequently, they occur in the first year of use of a combined hormonal contraceptive.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; If a blood clot forms in a vein in the leg or foot it can cause a deep vein thrombosis (DVT).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; If a blood clot travels from the leg and lodges in the lung it can cause a pulmonary embolism.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Very rarely a clot may form in a vein in another organ such as the eye (retinal vein thrombosis).</p><p>&nbsp;</p><p><strong>When is the risk of developing a blood clot in a vein highest?</strong></p><p>The risk of developing a blood clot in a vein is highest during the first year of taking a combined hormonal contraceptive for the first time. The risk may also be higher if you restart taking a combined hormonal contraceptive (the same product or a different product) after a break of 4 weeks or more.</p><p>After the first year, the risk gets smaller but is always slightly higher than if you were not using a combined hormonal contraceptive.</p><p>When you stop Lindynette your risk of a blood clot returns to normal within a few weeks.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>What is the risk of developing a blood clot?</strong></p><p>The risk depends on your natural risk of VTE and the type of combined hormonal contraceptive you are taking.</p><p>&nbsp;</p><p>The overall risk of a blood clot in the leg or lung (DVT or PE) with Lindynette is small.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Out of 10,000 women who are not using any combined hormonal contraceptive and are not pregnant, about 2 will develop a blood clot in a year.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Out of 10,000 women who are using a combined hormonal contraceptive that contains levonorgestrel, norethisterone, or norgestimate about 5-7 will develop a blood clot in a year.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Out of 10,000 women who are using a combined hormonal contraceptive that contains gestodene such as Lindynette, between about 9 and 12 women will develop a blood clot in a year.</p><p>The risk of having a blood clot will vary according to your personal medical history (see &lsquo;Factors that increase your risk of a blood clot in a vein&rsquo; below).</p><table border="1" cellspacing="0" cellpadding="0" style="width:624px"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Risk of developing a blood clot in a year</strong></p></td></tr><tr><td style="vertical-align:top"><p>Women who are <strong>not using</strong> a combined hormonal pill and are not pregnant.</p></td><td style="vertical-align:top"><p>About 2 out of 10,000 women</p></td></tr><tr><td style="vertical-align:top"><p>Women using a combined hormonal contraceptive pill containing l<strong>evonorgestrel, norethisterone or norgestimate</strong></p></td><td style="vertical-align:top"><p>About 5‑7&nbsp;out of 10,000&nbsp;women</p></td></tr><tr><td style="vertical-align:top"><p>Women using Lindynette</p></td><td style="vertical-align:top"><p>About 9‑12&nbsp;out of 10,000&nbsp;women</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Factors that increase your risk of a blood clot in a vein</strong></p><p>The risk of a blood clot with Lindynette is small but some conditions will increase the risk. Your risk is higher:</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; if you are very overweight (body mass index or BMI over 30kg/m2)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; if one of your immediate family has had a blood clot in the leg, lung or other organ at a young age (e.g. below the age of about 50). In this case you could have a hereditary blood clotting disorder</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; if you need to have an operation, or if you are off your feet for a long time because of an injury or illness, or you have your leg in a cast. The use of Lindynette may need to be stopped at least 4 weeks before surgery or while you are less mobile. If you need to stop Lindynette ask your doctor when you can start using it again.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; as you get older (particularly above about 35 years)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; if you gave birth less than a few weeks ago.</p><p>The risk of developing a blood clot increases the more conditions you have.</p><p>Air travel (&gt;4 hours) may temporarily increase your risk of a blood clot, particularly if you have some of the other factors listed.</p><p>It is important to tell your doctor if any of these conditions apply to you, even if you are unsure. Your doctor may decide that Lindynette needs to be stopped.</p><p>If any of the above conditions change while you are using Lindynette, for example a close family member experiences a thrombosis for no known reason, or you gain a lot of weight, tell your doctor.</p><p>&nbsp;</p><p><strong>BLOOD CLOTS IN AN ARTERY</strong></p><p>&nbsp;</p><p><strong>What can happen if a blood clot forms in an artery?</strong></p><p>Like a blood clot in a vein, a clot in an artery can cause serious problems. For example, it can cause a heart attack or a stroke.</p><p>&nbsp;</p><p><strong>Factors that increase your risk of a blood clot in an artery</strong></p><p>It is important to note that the risk of a heart attack or stroke from using Lindynette is very small but can increase:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; with increasing age (beyond about 35 years)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; if you smoke. When using a combined hormonal contraceptive like Lindynette, you are advised to stop smoking. If you are unable to stop smoking and are older than 35 your doctor may advise you to use a different type of contraceptive</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; if you are overweight</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; if you have high blood pressure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; if a member of your immediate family has had a heart attack or stroke at a young age (less than about 50). In this case you could also have a higher risk of having a heart attack or stroke</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; if you, or someone in your immediate family, have a high level of fat in the blood (cholesterol or triglycerides)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; if you get migraines, especially migraines with aura</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; if you have a problem with your heart (valve disorder, disturbance of the rhythm called atrial fibrillation)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; if you have diabetes.</p><p>&nbsp;</p><p>If you have more than one of these conditions or if any of them are particularly severe the risk of developing a blood clot may be increased even more.</p><p>&nbsp;</p><p>If any of the above conditions change while you are using Lindynette, for example you start smoking, a close family member experiences a thrombosis for no known reason, or you gain a lot of weight, tell your doctor.</p><p>&nbsp;</p><p><strong>2-4 &nbsp;&nbsp;&nbsp;The Pill and cancer</strong></p><p>While high dose Pills reduce your risk of cancer of the ovary and womb if used in the long term, it is not clear whether lower dose Pills like Lindynette also provide the same protective effects. However, it also seems that taking the Pill slightly increases your risk of&nbsp;<strong>cancer of the cervix</strong>&nbsp;&ndash; although this may be due to having sex without a condom, rather than the Pill. All women should have regular smear tests.</p><p>&nbsp;</p><p>If you have&nbsp;<strong>breast cancer</strong>, or have had it in the past, you should not take the Pill. The Pill slightly increases your risk of breast cancer. This risk goes up the longer you&rsquo;re on the Pill, but returns to normal within about 10 years of stopping it. Because breast cancer is rare in women under the age of 40, the extra cases of breast cancer in current and recent Pill users is small. For example:</p><p>Of 10,000 women who have&nbsp;<strong>never taken the Pill</strong>, about&nbsp;<strong>16</strong>&nbsp;will have breast cancer by the time they are 35 years old.</p><p>&nbsp;</p><p>Of 10,000 women who&nbsp;<strong>take the Pill for 5 years in their early twenties</strong>, about&nbsp;<strong>17&ndash;18</strong>&nbsp;will have breast cancer by the time they are 35 years old.</p><p>&nbsp;</p><p>Of 10,000 women who have&nbsp;<strong>never taken the Pill</strong>, about&nbsp;<strong>100</strong>&nbsp;will have breast cancer by the time they are 45 years old.</p><p>&nbsp;</p><p>Of 10,000 women who&nbsp;<strong>take the Pill for 5 years in their early thirties</strong>, about&nbsp;<strong>110</strong>&nbsp;will have breast cancer by the time they are 45 years old.</p><p>&nbsp;</p><p><strong>Your risk of breast cancer is higher:</strong></p><p>if you have a close relative (mother, sister or grandmother) who has had breast cancer</p><p>if you are seriously overweight</p><p>&nbsp;</p><p><strong>See a doctor as soon as possible if you notice any changes in your breasts,&nbsp;</strong>such as dimpling of the skin, changes in the nipple or any lumps you can see or feel.</p><p>Taking the Pill has also been linked to liver diseases, such as jaundice and non- cancer liver tumours, but this is rare. Very rarely, the Pill has also been linked with some forms of liver cancer in women who have taken it for a long time.</p><p>&nbsp;</p><p><strong>See a doctor as soon as possible if you get severe pain in your stomach, or yellow skin or eyes&nbsp;</strong>(jaundice). You may need to stop taking Lindynette.</p><p>&nbsp;</p><p><strong>2-5&nbsp; Psychiatric disorders:</strong></p><p>Some women using hormonal contraceptives including Lindynette have reported depression or depressed mood. Depression can be serious and may sometimes lead to suicidal thoughts. If you experience mood changes and depressive symptoms contact your doctor for further medical advice as soon as possible.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>2-6&nbsp; Taking other medicines</strong></p><p>If you ever need to take another medicine at the same time as being on the Pill, always tell your doctor, pharmacist or dentist that you&rsquo;re taking Lindynette. Also check the leaflets that come with all your medicines to see if they can be taken with hormonal contraceptives.</p><p>&nbsp;</p><p>Some medicines can have an influence on the blood levels of Lindynette and can stop it from working properly &ndash; for example:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; some medicines used to treat epilepsy</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; some medicines used to treat HIV and Hepatitis C Virus infections (so-called protease inhibitors and non-nucleoside reverse transcriptase inhibitors)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; griseofulvin (an anti-fungal medicine)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; certain antibiotics</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; certain sedatives (called &lsquo;barbiturates&rsquo;)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; St. John&rsquo;s Wort (a herbal remedy).</p><p>&nbsp;</p><p>If you do need to take one of these medicines, Lindynette may not be suitable for you or you may need to use extra contraception for a while. Your doctor, pharmacist or dentist can tell you if this is necessary and for how long.</p><p>&nbsp;</p><p><strong>Lindynette can also affect how well other medicines work.&nbsp;</strong></p><p>Your doctor may need to adjust the dose of your other medicine.</p><p>In addition, Lindynette can also interfere with the results of some blood tests, so always tell your doctor that you are taking Lindynette if you have a blood test.</p><p>Do not use Lindynette if you have hepatitis C and are taking the medicinal products containing ombitasvir / paritaprevir / ritonavir and dasabuvir or glecaprevir / pibrentasvir as this may cause increases in liver function blood test results (increase in ALT liver enzyme). Your doctor will prescribe another type of contraceptive prior to start of the treatment with these medicinal products. Lindynette can be restarted approximately 2 weeks after completion of treatment. See section &lsquo;Do not use Lindynette&rsquo;).</p><p>&nbsp;</p><p><strong>2-7 Taking Lindynette with food and drink</strong></p><p>There are no special instructions about food and drink while on Lindynette.</p><p>&nbsp;</p><p><strong>2-8 Pregnancy and Breast-feeding</strong></p><p><strong>Do not use Lindynette&nbsp;</strong>if you are pregnant. If you think you might be pregnant, do a pregnancy test to confirm that you are before you stop taking Lindynette.<strong>&nbsp;</strong></p><p>&nbsp;</p><p><strong>If you are breast-feeding,&nbsp;</strong>your doctor or family planning nurse may advise you not to take Lindynette. They will be able to suggest alternative contraception<strong>.&nbsp;</strong>Breast-feeding may not stop you getting pregnant.</p><p>&nbsp;</p><p><strong>2-9 Driving and using machines</strong></p><p>Lindynette has no known effect on the ability to drive or use machines.</p><p>&nbsp;</p><p><strong>2-10 Lindynette contains lactose and sucrose</strong></p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before using Lindynette.</p><p>This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>How to take Lindynette</strong></p><p>&nbsp;</p><p><strong>3</strong><strong>-1&nbsp;&nbsp;&nbsp; How to take it</strong></p><p>To prevent pregnancy, always take Lindynette as described below. Check with your doctor or family planning nurse if you are not sure.</p><p>&nbsp;</p><p><strong>Take Lindynette every day for 21 days</strong></p><p>Lindynette comes in strips of 21 pills, each marked with a day of the week.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Take your pill at the same time every day.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Start by taking a pill marked with the correct day of the week.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Follow the direction of the arrows on the strip. Take one pill each day, until you have finished all 21 pills.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Swallow each pill whole, with water if necessary. Do not chew the pill.</p><p>&nbsp;</p><p><strong>Then have seven pill-free days</strong></p><p>After you have taken all 21 pills in the strip, you have seven days when you take no pills. So, if you take the last pill of one pack on a Friday, you will take the first pill of your next pack on the Saturday of the following week.</p><p>Within a few days of taking the last pill from the strip, you should have a withdrawal bleed like a period. This bleed may not have finished when it is time to start your next strip of pills.</p><p>You don&rsquo;t need to use extra contraception during these seven pill-free days &ndash; as long as you have taken your pills correctly and start the next strip of pills on time.</p><p>&nbsp;</p><p><strong>Then start your next strip</strong></p><p>Start taking your next strip of Lindynette after the seven pill-free days &ndash; even if you are still bleeding. Always start the new strip on time.</p><p>As long as you take Lindynette correctly, you will always start each new strip on the same day of the week.</p><p>&nbsp;</p><p><strong>3-2&nbsp;&nbsp;&nbsp; Starting Lindynette</strong></p><p><strong>As a new user or starting the Pill again after a break</strong></p><p>It is best to take your first Lindynette pill on the first day of your next period. By starting in this way, you will have contraceptive protection with your first pill.</p><p>&nbsp;</p><p><strong>Changing to Lindynette from another contraceptive Pill</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;<strong>If you are currently on a 21-day Pill:</strong>&nbsp;start Lindynette the next day after the end of the previous strip. You will have contraceptive protection with your first pill. You will not have a bleed until after your first strip of Lindynette.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;<strong>If you are currently on a 28-day Pill</strong>: start taking Lindynette the day after your last active pill. You will have contraceptive protection with your first pill. You will not have a bleed until after your first strip of Lindynette.</p><p>&middot;&nbsp;&nbsp;&nbsp;<strong>Or, if you are taking a progestogen-only Pill</strong>&nbsp;(POP or &lsquo;mini Pill&rsquo;): start Lindynette on the first day of bleeding, even if you have already taken the progestogen-only Pill for that day. You will have contraceptive cover straight away.</p><p>&nbsp;</p><p><strong>Starting Lindynette after a miscarriage or abortion</strong></p><p>If you have had a miscarriage or an abortion&nbsp;<strong>during the first three months</strong>&nbsp;of pregnancy, your doctor may tell you to start taking Lindynette straight away. This means that you will have contraceptive protection with your first pill.</p><p>&nbsp;</p><p>If you have had a miscarriage or an abortion&nbsp;<strong>after the third month</strong>&nbsp;of pregnancy, ask your doctor for advice. You may need to use extra contraception, such as condoms, for a short time.</p><p>&nbsp;</p><p><strong>Contraception after having a baby</strong></p><p>If you have just had a baby, your doctor may advise you that Lindynette should be started 21 days after delivery provided that you are fully mobile. You do not have to wait for a period. You will need to use another method of contraception, such as a condom, until you start Lindynette and for the first 7 days of pill taking.</p><p>&nbsp;</p><p><strong>3-3&nbsp;&nbsp;&nbsp; A missed pill</strong></p><p><strong>If you are less than 12 hours late with a pill,</strong>&nbsp;take it straight away. Keep taking your pills at the usual time. This may mean taking two pills in one day. Don&rsquo;t worry &ndash; your contraceptive protection should not be reduced.</p><p>&nbsp;</p><p><strong>If you are more than 12 hours late with a pill</strong>, or you have missed more than one pill, your contraceptive protection may be reduced.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;<strong>Take the most recently missed pill&nbsp;</strong>as soon as you remember, even if it means taking two at once. Leave any earlier missed pills in the pack.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;<strong>Continue to take a pill every day for the next seven days&nbsp;</strong>at your usual time.</p><p>&middot;&nbsp;&nbsp;&nbsp;<strong>If you come to the end of a strip of pills&nbsp;</strong>during these seven days, start the next strip without taking the usual seven day break. You probably won&rsquo;t have a bleed until after you finish the second strip of pills, but don&rsquo;t worry. If you finish the second strip of pills and don&rsquo;t have a bleed, do a pregnancy test before starting another strip.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;<strong>Use extra contraception for seven days after missing a pill</strong>, such as condoms.</p><p>&middot;&nbsp;&nbsp;&nbsp;<strong>If</strong>&nbsp;you have missed one or more pills from the first week of your strip (days 1 to 7) and you had sex in that week, you could become pregnant. Contact your doctor, family planning nurse or pharmacist for advice as soon as possible. They may recommend you use emergency contraception.</p><p>&nbsp;</p><p><strong>If you have missed any of the pills in a strip, and you do not bleed in the first pill-free break, you may be pregnant. Contact your doctor or family planning clinic, or do a pregnancy test yourself.</strong></p><p><strong>If you start a new strip of pills late, or make your &lsquo;week off&rsquo; longer than seven days, you may not be protected from pregnancy</strong>.</p><p>If you had sex in the last seven days, ask your doctor, family planning nurse or pharmacist for advice. You may need to consider emergency contraception. You should also use extra contraception, such as a condom, for seven days.</p><p>&nbsp;</p><p><strong>3-4&nbsp;&nbsp;&nbsp;&nbsp; A lost pill</strong></p><p>If you lose a pill,</p><p><strong>Either</strong>&nbsp;take the last pill of the strip in place of the lost pill. Then take all the other pills on their proper days. Your cycle will be one day shorter than normal, but your</p><p>contraceptive protection won&rsquo;t be affected. After your seven pill-free days you will have a new starting day, one day earlier than before.</p><p><strong>Or</strong>&nbsp;if you do not want to change the starting day of your cycle, take a pill from a spare strip if you have one. Then take all the other pills from your current strip as usual. You can then keep the opened spare strip in case you lose any more pills.</p><p><strong>3-5&nbsp;&nbsp;&nbsp;&nbsp; If you are sick or have diarrhoea</strong></p><p>If you are sick (vomit) or have very bad diarrhoea within 4 hours of taking the Pill, your body may not get its usual dose of hormones from that pill. If you are&nbsp;<strong>better within 12 hours of taking Lindynette</strong>, follow the instructions in section 3.4 A lost pill, which describes how to take another pill.</p><p>If you are still sick or have diarrhoea&nbsp;<strong>more than 12 hours after taking Lindynette</strong>, see section 3.3, A missed pill.</p><p>&nbsp;</p><p><strong>Talk to your doctor if your stomach upset carries on or gets worse. He or she may recommend another form of contraception.</strong></p><p>&nbsp;</p><p><strong>3-6&nbsp;&nbsp;&nbsp; Missed a period &ndash; could you be pregnant?</strong></p><p>Occasionally, you may miss a withdrawal bleed. This could mean that you are pregnant, but that is very unlikely if you have taken your pills correctly. Start your next strip at the normal time. If you think that you might have put yourself at risk of pregnancy (for example, by missing pills or taking other medicines), or if you miss a second bleed, you should do a pregnancy test. You can buy these from the chemist or get a free test at your family planning clinic or doctors surgery. If you are pregnant, stop taking Lindynette and see your doctor.</p><p>&nbsp;</p><p><strong>3-7&nbsp;&nbsp;&nbsp; Taking more than one pill should not cause harm</strong></p><p>It is unlikely that taking more than one pill will do you any harm, but you may feel sick, vomit or bleed from the vagina. Even girls who have not yet started to menstruate but have accidentally taken this medicine may experience such bleeding.Talk to your doctor if you have any of these symptoms.</p><p>&nbsp;</p><p><strong>3-8&nbsp;&nbsp;&nbsp; When you want to get pregnant</strong></p><p>If you are planning a baby, it&rsquo;s best to use another method of contraception after stopping Lindynette until you have had a proper period. Your doctor or midwife relies on the date of your last natural period to tell you when your baby is due. However, it will not cause you or the baby any harm if you get pregnant straight away.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Possible side effects</strong></p><p>Like all medicines, Lindynette can cause side effects, although not everybody gets them. If you get any side effect, particularly if severe and persistent, or have any change to your health that you think may be due to Lindynette, please talk to your doctor.</p><p>An increased risk of blood clots in the veins (venous thromboembolism (VTE)) or blood clots in the arteries (arterial thromboembolism (ATE)) is present for all women using combined hormonal contraceptives. For more detailed information on the different risks from taking combined hormonal contraceptives please see section 2 &ldquo;What you need to know before you use Lindynette&rdquo;.</p><p><strong>Tell your doctor, pharmacist or family planning nurse&nbsp;</strong>if you are worried about any side effects which you think may be due to Lindynette.</p><p>&nbsp;</p><p><strong>4-1&nbsp;&nbsp;&nbsp; Serious side effects &ndash; see a doctor straight away</strong></p><p>&nbsp;</p><p><strong>Rare side effects</strong>&nbsp;(between 1 and 10 in every 10,000 users may be affected)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; harmful blood clots in a vein or artery for example:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in a leg or foot (i.e. DVT)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in a lung (i.e. PE)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart attack</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stroke</p><p>&nbsp;</p><p>&nbsp;mini-stroke or temporary stroke-like symptoms, known as a transient ischaemic attack (TIA)</p><p>&nbsp;blood clots in the liver, stomach/intestine, kidneys or eye.</p><p>&nbsp;</p><p>The chance of having a blood clot may be higher if you have any other conditions that increase this risk (see section 2 for more information on the conditions that increase risk for blood clots and the symptoms of a blood clot).</p><p>&nbsp;</p><p><strong>Signs of a blood clot</strong>&nbsp;(see section 2.3 &lsquo;Blood clots&rsquo;)</p><p>&nbsp;</p><p><strong>Signs of a severe allergic reaction or worsening of hereditary angioedema:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the hands, face, lips, mouth, tongue or throat. A swollen tongue/throat may lead to difficulty swallowing and breathing</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a red bumpy rash (hives) and itching.</p><p>&nbsp;</p><p><strong>Signs of breast cancer include:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp; dimpling of the skin</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; changes in the nipple</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; any lumps you can see or feel.</p><p>&nbsp;</p><p><strong>Signs of cancer of the cervix include:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp; vaginal discharge that smells and/or contains blood</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; unusual vaginal bleeding</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; pelvic pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; painful sex.</p><p>&nbsp;</p><p><strong>Signs of severe liver problems include:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp; severe pain in your upper abdomen</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; yellow skin or eyes (jaundice)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the liver (hepatitis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; your whole body starts itching.</p><p>&nbsp;</p><p><strong>If you think you may have any of these, see a doctor straight away. You may need to stop taking Lindynette.</strong></p><p>&nbsp;</p><p><strong>4-2&nbsp;&nbsp;&nbsp; Less serious side effects</strong></p><p><strong>Common side effects&nbsp;</strong>(between 100 and 1000 in every 10,000 users may be affected)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; feeling sick</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; stomach ache</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; putting on weight</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; headaches</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; depressive moods or mood swings</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; sore or painful breasts</p><p>&nbsp;</p><p><strong>Uncommon side effects</strong>&nbsp;(between 10 and 100 in every 10,000 users may be affected)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; being sick and stomach upsets</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; fluid retention</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; migraine</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; loss of interest in sex</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; breast enlargement</p><p>-&nbsp; skin rash, which may be itchy</p><p>&nbsp;</p><p><strong>Rare side effects</strong>&nbsp;(between 1 and 10 in every 10,000 users may be affected)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; poor tolerance of contact lenses</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; losing weight</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; increase of interest in sex</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; vaginal or breast discharge</p><p>&nbsp;</p><p><strong>Other side effects reported</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Bleeding and spotting between your periods can sometimes occur for the first few months but this usually stops once your body has adjusted to Lindynette. If it continues, becomes heavy or starts again, contact your doctor (see section 4.3).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Chloasma (yellow brown patches on the skin). This may happen even if you have been using Lindynette for a number of months. Chloasma may be reduced by avoiding too much sunlight and/or UV lamps</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Occurrence or deterioration of the movement disorder chorea</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Ulcerative colitis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Conditions that may worsen during pregnancy or previous use of the Pill:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; yellowing of the skin (jaundice)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; persistent itching (pruritus)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; kidney or liver problems</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gall stones</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain rare medical conditions such as systemic lupus erythematosus</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blister-like rash (herpes gestationis) whilst pregnant</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an inherited form of deafness (otosclerosis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Crohn&rsquo;s disease</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a personal or family history of a form of sickle cell disease</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of body parts (hereditary angioedema)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an inherited disease called porphyria</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cancer of the cervix</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>Tell your doctor, pharmacist or family planning nurse if you are worried about any side effects which you think may be due to Lindynette. Also tell them if any existing conditions get worse while you are taking Lindynette.</strong></p><p>&nbsp;</p><p><strong>4-3&nbsp;&nbsp;&nbsp; Bleeding between periods should not last long</strong></p><p>A few women have a little unexpected bleeding or spotting while they are taking Lindynette, especially during the first few months. Normally, this bleeding is nothing to worry about and will stop after a day or two. Keep taking Lindynette as usual. The problem should disappear after the first few strips.</p><p>You may also have unexpected bleeding if you are not taking your pills regularly, so try to take your pill at the same time every day. Also, unexpected bleeding can sometimes be caused by other medicines.</p><p>&nbsp;</p><p><strong>Make an appointment to see your doctor if you get breakthrough bleeding or spotting that:</strong></p><p>carries on for more than the first few months</p><p>starts after you&rsquo;ve been taking Lindynette for a while</p><p>carries on even after you&rsquo;ve stopped taking Lindynette.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet.</p><p>By reporting side effects, you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Arabia:</p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="Text_x0020_Box_x0020_1" o:spid="_x0000_s1026"
  type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
  margin-left:79.45pt;margin-top:13.4pt;width:436.15pt;height:77.65pt;
  z-index:251657728;visibility:visible;mso-wrap-distance-left:0;
  mso-wrap-distance-right:0;mso-position-horizontal-relative:page' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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" o:allowincell="f" filled="f" strokeweight=".33864mm">
  <v:textbox style='mso-next-textbox:#Text_x0020_Box_x0020_1' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoListParagraph style='margin-top:.35pt;margin-right:0in;
     margin-bottom:0in;margin-left:.25in;margin-bottom:.0001pt;mso-add-space:
     auto;text-indent:-.2in;mso-list:l0 level1 lfo2;tab-stops:.25in;punctuation-wrap:
     simple;mso-line-break-override:restrictions'><![if !supportLists]><span
     lang=EN-GB style='font-size:11.0pt;font-family:Symbol;mso-fareast-font-family:
     Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:EN-GB;mso-fareast-language:
     EN-GB'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
     </span></span></span><![endif]><span dir=LTR></span><span lang=EN-GB
     style='font-size:11.0pt;mso-fareast-font-family:Verdana;mso-ansi-language:
     EN-GB;mso-fareast-language:EN-GB'>The National Pharmacovigilance and Drug
     Safety Centre <span style='mso-spacerun:yes'> </span>(NPC)<o:p></o:p></span></p>
     <p class=MsoBodyText style='margin-left:50.35pt;mso-add-space:auto;
     text-indent:-.2in;line-height:normal;mso-list:l0 level2 lfo2;punctuation-wrap:
     simple;mso-line-break-override:restrictions'><![if !supportLists]><span
     lang=EN-GB style='font-size:11.0pt;font-family:"Courier New";mso-fareast-font-family:
     "Courier New";mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span
     style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;
     </span></span></span><![endif]><span dir=LTR></span><span lang=EN-GB
     style='font-size:11.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
     Verdana;mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'>Fax: +966-11-205-7662<o:p></o:p></span></p>
     <p class=MsoBodyText style='margin-left:50.35pt;mso-add-space:auto;
     text-indent:-.2in;line-height:normal;mso-list:l0 level2 lfo2;punctuation-wrap:
     simple;mso-line-break-override:restrictions'><![if !supportLists]><span
     lang=EN-GB style='font-size:11.0pt;font-family:"Courier New";mso-fareast-font-family:
     "Courier New";mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span
     style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;
     </span></span></span><![endif]><span dir=LTR></span><span lang=EN-GB
     style='font-size:11.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
     Verdana;mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'>Phone number: </span><span
     dir=RTL></span><span lang=AR-SA dir=RTL style='font-size:11.0pt;
     font-family:"Times New Roman",serif;mso-fareast-font-family:Verdana;
     mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span dir=RTL></span>19999</span><span
     lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
     mso-fareast-font-family:Verdana;mso-ansi-language:EN-GB;mso-fareast-language:
     EN-GB'><o:p></o:p></span></p>
     <p class=MsoBodyText style='margin-left:50.35pt;mso-add-space:auto;
     text-indent:-.2in;line-height:normal;mso-list:l0 level2 lfo2;punctuation-wrap:
     simple;mso-line-break-override:restrictions'><![if !supportLists]><span
     lang=EN-GB style='font-size:11.0pt;font-family:"Courier New";mso-fareast-font-family:
     "Courier New";mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span
     style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;
     </span></span></span><![endif]><span dir=LTR></span><span lang=EN-GB
     style='font-size:11.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
     Verdana;mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'>E-mail: <a
     href="mailto:npc.drug@sfda.gov.sa"><span style='color:windowtext;
     text-decoration:none;text-underline:none'>npc.drug@sfda.gov.sa</span></a><o:p></o:p></span></p>
     <p class=MsoBodyText style='margin-top:2.3pt;margin-right:0in;margin-bottom:
     0in;margin-left:50.35pt;margin-bottom:.0001pt;mso-add-space:auto;
     text-indent:-.2in;line-height:normal;mso-list:l0 level2 lfo2;punctuation-wrap:
     simple;mso-line-break-override:restrictions'><![if !supportLists]><span
     lang=EN-GB style='font-size:11.0pt;font-family:"Courier New";mso-fareast-font-family:
     "Courier New";mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span
     style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;
     </span></span></span><![endif]><span dir=LTR></span><span lang=EN-GB
     style='font-size:11.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
     Verdana;mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'>Website: <a
     href="http://www.sfda.gov.sa/npc"><span style='color:windowtext;
     text-decoration:none;text-underline:none'>www.sfda.gov.sa/npc</span></a><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="587" height="108" alt="Text Box: -	The National Pharmacovigilance and Drug Safety Centre  (NPC)
o	Fax: +966-11-205-7662
o	Phone number: 19999
o	E-mail: npc.drug@sfda.gov.sa
o	Website: www.sfda.gov.sa/npc
" src="file:///C:/Users/101623/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other GCC Slates:</p><p>Please contact the relevant competent authority.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use Lindynette after the expiry date (Exp.:) which is stated on the blister pack or the carton. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Do not store above 30&deg;C. Store in the original package in order to protect from light and moisture.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Lindynette contains</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substances are 75&nbsp;micrograms of gestodene and 30&nbsp;micrograms of ethinylestradiol in each coated tablet.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are Sodium calcium edetate, Magnesium stearate, Silica colloidal anhydrous, Povidone, Maize starch, Lactose monohydrate, &ldquo;Quinoline&rdquo; Yellow (E 104), Titanium dioxide, Macrogol 6000, Talc, Calcium carbonate, Sucrose.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	What Lindynette looks like and contents of the pack
	Coated tablets: Yellow, round, biconvex sugar-coated tablets. The breaking surface is white.
	
	Packaging:
21 coated tablets in PVC/PVDC//Al blister, in folded carton.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p><strong>Marketing Authorisation Holder</strong></p><p>AJA Pharmaceutical Industries Company, Ltd.</p><p>Hail Industrial City MODON, Street No 32</p><p>PO Box 6979 , Hail 55414</p><p>Kingdom of Saudi Arabia</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>Gedeon Richter Plc.</p><p>H-1103 Budapest</p><p>Gy&ouml;mrői &uacute;t 19-21.</p><p>Hungary</p><p>OGYI-T-8830/03&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (1&times;21 coated tablets)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	This leaflet was last revised in October 2023.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">1-<strong> </strong><strong>ما</strong><strong> </strong><strong>هو</strong><strong> </strong><strong>ليندينيت</strong><strong> </strong><strong>وفيما</strong><strong> </strong><strong>يستخدم؟</strong></p><p dir="RTL">ليندينيت هي حبوب منع الحمل المركبة عن طريق الفم ) &laquo;الحبة &raquo;(. أنت تأخذينه لمنعك</p><p dir="RTL">من الحمل. تحتوي موانع الحمل هذه على نوعين من الهرمونات الجنسية الأنثوية ، الإستروجين</p><p dir="RTL">والبروجستيرون. تمنع هذه الهرمونات الحمل من خلال العمل بثلاث طرق: عن طريق</p><p dir="RTL">منع إطلاق البويضة من المبيضين. عن طريق جعل السائل (المخاط) في عنق الرحم</p><p dir="RTL">أكثر سمكًا ، مما يجعل دخول الحيوانات المنوية إلى الرحم أكثر صعوبة ؛ ومن خلال</p><p dir="RTL">منع بطانة رحمك من السماكة بدرجة تكفي لنمو البويضة فيها.</p><p dir="RTL">أقراص ليندينيت مدتها 21 يومًا - تأخذ قرص كل يوم لمدة 21 يومًا ، تليها 7 أيام بدون</p><p dir="RTL">أقراص. لن تحميك ليندينيت من الأمراض المنقولة جنسياً ، مثل الكلاميديا أو فيروس نقص</p><p dir="RTL">المناعة البشرية. فقط الواقي الذكري يمكن أن يساعد في القيام بذلك.</p><p dir="RTL">يجب تناول ليندينيت حسب التوجيهات لمنع الحمل.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>- ما يجب عليك معرفته قبل استخدامك لليندينيت.</strong></p><p dir="RTL"><strong>ملاحظات عامة.</strong></p><p dir="RTL">يجب عليك قراءة المعلومات الخاصة بجلطات الدم في القسم 2 قبل البدء في استخدام لندينيت . ومن المهم بشكل خاص قراءة أعراض الجلطة الدموية &ndash; انظري القسم &laquo; 2.3 جلطات الدم .&raquo;</p><p dir="RTL">من المهم فهم فوائد ومخاطر تناول حبوب منع الحمل قبل البدء في استخدامها، أو عند تحديد ما إذا كنت ستستمرين في تناولها. وعلى الرغم من أن حبوب منع الحمل</p><p dir="RTL">مناسبة لمعظم النساء الأصحاء إلا أنها ليست مناسبة للجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبري طبيبك إذا كنت تعانين أي من الأمراض أو عوامل الخطر المذكورة في</p><p dir="RTL">هذه النشرة</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>قبل البدء في تناول حبوب منع الحمل</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">-سوف يسألك طبيبك عن المشاكل الطبية الخاصة بك أو بأسرتك، وسوف</p><p dir="RTL">يقوم بفحص ضغط الدم الخاص بك، واستبعاد احتمال كونك حاملا. قد</p><p dir="RTL">تحتاجين أيضًا إلى فحوصات أخرى، مثل فحص الثدي، ولكن فقط إذا كانت هذه</p><p dir="RTL">الفحوصات ضرورية بالنسبة لك أو إذا كان لديك أي مخاوف خاصة.</p><p dir="RTL">-بينما تتناولين حبوب منع الحمل ستحتاجين إلى إجراء فحوصات منتظمة مع طبيبك أو مع ممرضة تنظيم الأسرة، عادة عندما تحتاجين إلى وصفة طبية أخرى لحبوب منع الحمل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-يجب عليك إجراء اختبارات مسحة عنق الرحم لفحص سرطان الرحم بانتظام.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-افحصي الثديين والحلمتين كل شهر للتحقق من أي تغييرات - أخبري طبيبك</p><p dir="RTL">إذا رأيت أو شعرت بأي شيء غريب، مثل وجود كتل أو ترصع في الجلد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-إذا كنت بحاجة لإجراء فحص دم، أخبري طبيبك بأنك تتناولين حبوب منع</p><p dir="RTL">الحمل، حيث أن حبوب منع الحمل يمكن أن تؤثر على نتائج بعض الاختبارات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-إذا كنت ستجرين عملية جراحية، تأكدي من أن طبيبك يعلم عنها. فقد</p><p dir="RTL">تحتاجين إلى التوقف عن تناول حبوب منع الحمل على الأقل 4 أسابيع قبل</p><p dir="RTL">العملية. وهذا للحد من خطر حدوث جلطة دموية (انظري القسم 2.3). سوف</p><p dir="RTL">يخبرك طبيبك متى يمكنك البدء في تناول حبوب منع الحمل مرة أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;1-2</strong><strong>متى يجب عليك عدم استخدام ليندينيت؟</strong></p><p dir="RTL">لا يجب عليك استخدام ليندينيت إذا كنت مصابة بأي من الحالات المذكورة أدناه. إذا</p><p dir="RTL">كنت مصابة بأي من الحالات المذكورة أدناه، يجب أن تخبري طبيبك. سيتناقش معك</p><p dir="RTL">طبيبك عن أي وسيلة من وسائل منع الحمل ستكون أكثر ملاءمة لك..</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدمي ليندينيت:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك) أو سبق أن أصبت (بجلطة دموية في أحد الأوعية الدموية في</p><p dir="RTL">الساقين (تجلط الأوردة العميقة ((DVT) أو في الرئتين (انصمام (انسداد) رئوي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PE))) أو في أي أعضاء أخرى</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعلمين أن لديك اضطرابًا يؤثر على تخثر الدم - على سبيل المثال،</p><p dir="RTL">نقص البروتين C، أو نقص البروتين S، أو نقص مضاد الثرومبين الثالث، أو</p><p dir="RTL">العامل الخامس لايدن أو الأجسام المضادة لمضادات الدهون الفوسفورية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت بحاجة إلى إجراء عملية جراحية أو إذا كنت لن تقفي على قدميك</p><p dir="RTL">لفترة طويلة (انظري قسم &laquo;جلطات الدم)&raquo;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد كنت قد أصبت من قبل بأزمة قلبية أو سكتة دماغية،</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعانين (أو قد عانيتِ في أي وقت مضى (من ذبحة صدرية) وهي حالة</p><p dir="RTL">تسبب ألمًا حادًا في الصدر وقد تكون علامة أولى على حدوث نوبة قلبية (أو</p><p dir="RTL">نوبة إقفارية عابرة) TIA - أعراض السكتة الدماغية المؤقتة)</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابة بأي من الأمراض التالية والتي قد تزيد من خطر حدوث جلطة</p><p dir="RTL">في الشرايين:</p><p dir="RTL">&nbsp;</p><p dir="RTL">1.&nbsp;&nbsp; مرض السكر الشديد مع تلف الأوعية الدموية</p><p dir="RTL">&nbsp;</p><p dir="RTL">2.&nbsp;&nbsp; ضغط دم مرتفع جدا</p><p dir="RTL">&nbsp;</p><p dir="RTL">3.&nbsp;&nbsp; مستوى عال جداً من الدهون في الدم (الكوليسترول أو الدهون الثلاثية)</p><p dir="RTL">&nbsp;</p><p dir="RTL">4.&nbsp;&nbsp; حالة تعرف باسم فرط الهوموسيستين في الدم</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابة (أو كنت قد أصبت في أي وقت مضى) بنوع من الصداع النصفي يسمى &lsaquo;الصداع النصفي مع أوْرَة&rsaquo;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابة أو كنت قد أصبت في أي وقت مضى بسرطان الثدي</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد أصبت في أي وقت مضى بمرض كبدي حاد، وأخبرك طبيبك أن نتائج اختبار وظائف الكبد لم تعد إلى طبيعتها بعد</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد أصبت في أي وقت مضى بأورام في الكبد</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعانين من الحساسية (فرط الحساسية) تجاه أي من مكونات ليندينيت.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدمي لندينيت إذا كنت مصابة بالتهاب الكبد الوبائي (سي) وتتناولين منتجات طبية تحتوي على أومبيتاسفير / باريتابريفير / ريتونافير وداسابوفير أو جليكابريفير /</p><p dir="RTL">بيبرنتاسفير (أنظري أيضًا قسم &laquo;تناول أدوية أخرى)&raquo;</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبري طبيبك أو ممرضة تنظيم الأسرة إذا كان لديك أي أمراض أو مشاكل طبية</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>2-2 متى يجب إعطاء عناية خاصة مع لندينيت</strong></p><p dir="RTL">متى يجب عليك الاتصال بطبيبك؟</p><p dir="RTL"><u>التماس عناية طبية عاجلة</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا لاحظت أي علامات محتملة لجلطة دموية فقد يعني هذا أنك تعانين من</p><p dir="RTL">جلطة دموية في الساق (أي تخثر الوريد العميق)، أو جلطة دموية في الرئة (أي</p><p dir="RTL">انصمام (انسداد) رئوي (أو نوبة قلبية أو سكتة دماغية) انظري قسم &laquo;جلطات</p><p dir="RTL">الدم&raquo; أدناه).</p><p dir="RTL">للحصول على وصف لأعراض هذه الآثار الجانبية الخطيرة، يرجى الرجوع إلى قسم</p><p dir="RTL">&laquo;كيفية التعرف على الجلطة الدموية.&raquo;</p><p dir="RTL">من الممكن لبعض الحالات المذكورة أدناه أن تصبح أسوأ مع تناول حبوب منع الحمل.</p><p dir="RTL">أو قد يعني هذا أنها أقل ملاءمة لك. قد يكون لا يزال بإمكانك تناول ليندينيت ولكن</p><p dir="RTL">عليك أن تتوخي عناية خاصة وتجري فحوصات أكثر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخبري طبيبك إذا كان أي من الحالات التالية ينطبق عليك.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تطورت الحالة أو ازدادت سوءًا أثناء استخدام ليندينيت، فيجب عليك أيضًا إخبار طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابة بمرض كرون أو التهاب القولون التقرحي (مرض التهاب الأمعاء المزمن)</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابة بمرض الذئبة الحمامية الجهازية (SLE &ndash; وهو مرض يؤثر على نظام الدفاع الطبيعي الخاص بك)</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذاكنت مصابة بمتلازمة انحلال الدم اليوريمية (HUS- وهو اضطراب في تخثر الدم يتسبب في فشل الكليتين)</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابة بفقر الدم المنجلي (مرض وراثي في خلايا الدم الحمراء)</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك التهاب في البنكرياس</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مستويات مرتفعة من الدهون في الدم )فرط ثلاثي جليسريد الدم( أو تاريخ عائلي إيجابي لهذه الحالة. ارتبط فرط ثلاثي جليسريد الدم مع زيادة خطر الإصابة بالتهاب البنكرياس</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت بحاجة إلى إجراء عملية جراحية أو إذا كنت لن تقفي على قدميك لفترة طويلة )أنظري قسم &laquo;جلطات الدم )&raquo;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد أنجبت حديثا فقد تكوني في خطر متزايد من جلطات الدم. يجب عليك أن تسألي طبيبك متى يمكنك البدء في تناول ليندينيت بعد الولادة</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك التهاب في الأوردة تحت الجلد (التهاب الوريد الخثاري السطحي)</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك دوالي</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابة بمرض السكر</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت أنت أو أحد أفراد عائلتك المقربين قد عانيتم في أي وقت مضى من</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في القلب أو الدورة الدموية مثل ارتفاع ضغط الدم</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت أنت أو أحد أفراد عائلتك المقربين قد عانيتم في أي وقت مضى من مشاكل في تخثر الدم</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابة بمرض وراثي يسمى البورفيريا</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعانين من زيادة الوزن (السمنة)</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كن تعانين من الصداع النصفي</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعانين من أي مرض وازداد سوءًا أثناء الحمل أو أثناء أي استخدام سابق</p><p dir="RTL">لحبوب منع الحمل (انظري قسم 4.2)</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>3-2 جلطات الدم</strong></p><p dir="RTL">إن استخدام وسيلة منع حمل هرمونية مركبة مثل ليندينيت يزيد من خطر الإصابة</p><p dir="RTL">بجلطة دموية مقارنة بعدم الاستخدام. وفي حالات نادرة يمكن للجلطة الدموية أن</p><p dir="RTL">تسد الأوعية الدموية وتتسبب في مشاكل خطيرة.</p><p dir="RTL">يمكن للجلطات الدموية أن تظهر في:</p><p dir="RTL">&nbsp;</p><p dir="RTL">في الأوردة (والتي يشار إليها باسم &laquo;تخثر وريدي &laquo;جلطات دموية وريدية &raquo; أو</p><p dir="RTL">؛ VTE) في الشرايين (والتي يشار إليها باسم &laquo;تخثر شرياني&raquo; &nbsp;&laquo; جلطات دموية</p><p dir="RTL">الشريانية&raquo; أو ATE).</p><p dir="RTL">التعافي من الجلطات الدموية ليس دائما كاملا. ونادرًا ما تكون هناك آثار دائمة</p><p dir="RTL">خطيرة أو، نادرًا جدًا، ما قد تكون قاتلة.</p><p dir="RTL">من المهم أن نتذكر أن الخطر العام لوجود جلطة دموية ضارة بسبب ليندينيت</p><p dir="RTL">يكون صغير.</p><p dir="RTL"><strong>كيفية التعرف على الجلطة الدموية</strong></p><p dir="RTL">اطلبي عناية طبية عاجلة إذا لاحظت أي من العلامات أو الأعراض التالية.</p><p dir="RTL"><strong>-هل تعانين من أي من هذه الأعراض؟</strong></p><p dir="RTL"><strong>-ما الذي ربما تكوني تعانين منه؟</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تجلط الأوردة العميقة</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم في ساق واحدة أو على طول الوريد في الساق أو القدم خاصة عندما يكون مصحوبا ب:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم أو ضعف في الساق والذي يمكن الشعور به فقط عند الوقوف أو المشي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الدفء في الساق المصابة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير في لون جلد الساق على سبيل المثال التحول إلى لون شاحب أو لون أحمر أو أزرق</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>انصمام (انسداد) رئوي</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق تنفس مفاجئ غير مبرر أو سرعة التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سعال مفاجئ دون أسباب واضحة، والذي قد يكون مصحوبا بدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم حاد في الصدر قد يزداد مع التنفس العميق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوار شديد أو دوخة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضربات قلب سريعة أو غير منتظمة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم شديد في معدتك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت غير متأكدة، تحدثي مع طبيبك حيث أن بعض هذه الأعراض مثل السعال أو ضيق التنفس قد تعتقدين خطأ أنها حالة أخف مثل عدوى الجهاز التنفسي (مثل&bdquo;نزلات البرد الشائعة&ldquo;).</p><p dir="RTL"><strong>خثار الوريد الشبكي (جلطة دموية في العين)</strong></p><p dir="RTL">الأعراض الأكثر شيوعا حدوثها في عين واحدة:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان فوري للرؤية أو عدم وضوح الرؤية غير المؤلم الذي يمكن أن يتطور</p><p dir="RTL">إلى فقدان الرؤية</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نوبة قلبية</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الصدر، الاحساس بعدم الراحة، ضغط، ثقل الشعور بالضغط أو الامتلاء في الصدر أو الذراع أو تحت عظم الصدر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الامتلاء أو عسر الهضم أو الشعور بالاختناق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بعدم الارتياح في الجزء العلوي من الجسم يشع إلى الظهر والفك والحنجرة والذراع والمعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعرق، غثيان، قيء أو دوار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف شديد، أو قلق، أو ضيق في التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضربات قلب سريعة أو غير منتظمة</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>السكتة الدماغية</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف مفاجئ أو خدر في الوجه أو الذراع أو الساق، خاصة في جانب واحد من الجسم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتباك مفاجئ أو صعوبة في الكلام أو الفهم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلة مفاجئة في الرؤية في إحدى العينين أوكلتاهما</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبات مفاجئة في المشي أو دوخة أو فقدان التوازن أو التنسيق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع مفاجئ أو شديد أو لفترات طويلة مع عدم وجود سبب معروف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوعي أو الإغماء مع أو بدون نوبة صرع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في بعض الأحيان يمكن أن تكون أعراض السكتة الدماغية قصيرة مع معافاة شبه فورية وكاملة، ولكن يجب عليك السعي للحصول على عناية طبية عاجلة لأنك قد تكونين عرضة لخطر الإصابة بسكتة دماغية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>جلطات دموية تسد أوعية دموية أخرى</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم أحد الأطراف وتغير طفيف إلى اللون الأزرق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم شديد في معدتك (البطن الحاد)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>راجعي الطبيب في أسرع وقت ممكن. لا تتناولي المزيد من ليندينيت حتى</strong></p><p dir="RTL"><strong>يخبرك طبيبك أن بإمكانك ذلك. وأثناء ذلك، استخدمي وسيلة أخرى لمنع الحمل</strong></p><p dir="RTL"><strong>مثل الواقي الذكري.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong><u>الجلطات الدموية في الوريد</u></strong></p><p dir="RTL"><strong>ماذا يمكن أن يحدث إذا تكونت جلطة دموية في الوريد؟</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تم الربط بين استخدام وسائل منع الحمل الهرمونية المركبة وزيادة خطر حدوث جلطات دموية في الوريد (تخثر وريدي). ومع ذلك، فإن هذه الآثار الجانبية نادرة. وفي أغلب الأحيان، تحدث في السنة الأولى من استخدام وسائل منع الحمل الهرمونية المركبة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تكونت جلطة دموية في وريد الساق أو القدم فإنها يمكن أن تتسبب في</p><p dir="RTL">جلطة وريدية عميقة (DVT).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا انتقلت الجلطة الدموية من الساق واستقرت في الرئة فمن الممكن أن تتسبب في انصمام (انسداد( رئوي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالات نادرة جداً يمكن أن تتكون الجلطة في أحد أوردة عضو آخر مثل العين</p><p dir="RTL">(تخثر الوريد الشبكي).</p><p dir="RTL"><strong>متى يكون خطر حدوث جلطة دموية في الوريد أعلى؟</strong></p><p dir="RTL">خطر الإصابة بتجلط دموي في الوريد يكون أعلى خلال السنة الأولى من تناول</p><p dir="RTL">وسيلة منع حمل هرمونية مركبة للمرة الأولى. كما يمكن أن يزداد هذا الخطر أيضا إذا عاودت تناول وسيلة منع الحمل المركبة بعد انقطاع دام 4 أسابيع أو أكثر (نفس المنتج أو منتج مختلف.</p><p dir="RTL">وبعد السنة الأولى، يصبح الخطر أقل ولكنه يظل دائماً أعلى قليلاً مما لو كنت لا</p><p dir="RTL">تستخدمين وسائل منع حمل هرمونية مركبة.</p><p dir="RTL">عندما تتوقفين عن تناول ليندينيت، يعود خطر حدوث جلطة دموية إلى طبيعته في</p><p dir="RTL">غضون أسابيع قليلة.</p><p dir="RTL"><strong>ما هي خطورة الإصابة بجلطة دموية؟</strong></p><p dir="RTL">المخاطر تعتمد على المخاطر الطبيعية لحدوث جلطات دموية وريدية (VTE) لديك ونوع</p><p dir="RTL">حبوب منع الحمل الهرمونية المركبة التي تستخدمينها.</p><p dir="RTL">الخطر الكلي لحدوث جلطة دموية في الساق أو الرئة (DVT أو PE) مع تناول</p><p dir="RTL">ليندينيت يكون صغيرا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من بين 10.000 سيدة لا يستخدمن أي وسيلة هرمونية مركبة لمنع الحمل ولسن حوامل، قد يصاب منهن حوالي سيدتين بجلطة دموية في السنة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من بين 10.000 سيدة يستخدمن وسيلة منع حمل هرمونية مركبة تحتوي على ليفونورجيستريل أو نوريثيستيرون أو نورجيستيمات، قد تصاب منهن حوالي 7-5 سيدات بجلطة دموية في السنة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من بين 10.000 سيدة يستخدمن وسيلة منع حمل هرمونية مركبة تحتوي على جيستودين مثل ليندينيت، قد تصاب منهن حوالي 9 - 12 سيدات بجلطة دموية في السنة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن خطر الإصابة بجلطة دموية يختلف بحسب تاريخك الطبي الشخصي (انظري &laquo;العوامل التي تزيد من خطر حدوث جلطة دموية في الوريد &raquo; أدناه).</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خطر الإصابة بجلطة دموية في السنة</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النساء اللاتي لا تستخدمن حبوب منع حمل هرمونية مركبة ولسن حوامل: حوالي سيدتين من أصل 10,000 سيدة</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النساء اللاتي يستخدمن حبوب منع حمل هرمونية مركبة تحتوي على ليفونورجيستريل أو نوريثيستيرون أو نورجيستيمات: حوالي 5- 7 من أصل 10.000 سيدة</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النساء اللاتي يستخدمن ليندينيت: حوالي 9- 12 من أصل 10.000 سيدة</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>العوامل التي تزيد من خطر حدوث جلطة دموية في الوريد</strong></p><p dir="RTL">إن خطر حدوث جلطة دموية مع تناول ليندينيت صغير، ولكن بعض الحالات ستزيد من</p><p dir="RTL">هذه المخاطر. خطر الإصابة لديك سيكون أعلى:</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعانين من زيادة كبيرة في الوزن (مؤشر كتلة الجسم (BMI) أكثر من</p><p dir="RTL">30 كجم/م 2)</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان أحد أفراد أسرتك قد أصيب في أي وقت مضى بجلطة دموية فالساق أو الرئة أو أي عضو آخر من أعضاء الجسم في سن مبكرة (على سبيل المثال أقل من 50 عامًا تقريبًا). في هذه الحالة يمكن أن يكون لديك اضطراب وراثي في تخثر الدم</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت بحاجة لإجراء عملية جراحية، أو إذا كنت لن تقفي على قدميك</p><p dir="RTL">لفترة طويلة بسبب إصابة أو مرض، أو إذا كانت ساقك في الجبس. قد تحتاجين</p><p dir="RTL">للتوقف عن تناول ليندينيت على الأقل 4 أسابيع قبل إجراء الجراحة أو في الفترة</p><p dir="RTL">التي تقل بها حركتك. إذا كنت بحاجة إلى إيقاف ليندينيت، اسألي طبيبك متى</p><p dir="RTL">يمكنك البدء في استخدامه مرة أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كلما تقدمت في السن (خاصة فوق عمر 35 سنة تقريبًا)</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد أنجبت قبل أسابيع قليلة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ويزداد خطر حدوث الجلطة الدموية كلما زادت هذه الحالات التي لديك.</strong></p><p dir="RTL">السفر جوا (أكثر من 4 ساعات) قد يزيد من خطر حدوث جلطة دموية بشكل</p><p dir="RTL">مؤقت، خاصة إذا كان لديك بعض العوامل الأخرى المذكورة.</p><p dir="RTL">من المهم أن تخبري طبيبك إذا كان أي من هذه الحالات ينطبق عليك، حتى إذا لم</p><p dir="RTL">تكوني متأكدة. قد يقرر طبيبك أنك بحاجة إلى إيقاف ليندينيت.</p><p dir="RTL">إذا تغيرت أي من الحالات المذكورة أعلاه أثناء استخدام ليندينيت، على سبيل المثال إذا</p><p dir="RTL">أصيب أحد أفراد الأسرة المقربين بجلطة بدون سبب معروف، أو إذا اكتسبت الكثير</p><p dir="RTL">من الوزن، أخبري طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجلطات الدموية في الشريان</strong></p><p dir="RTL"><strong>ماذا يمكن أن يحدث إذا تكونت جلطة دموية في الشريان؟</strong></p><p dir="RTL">مثل الجلطة الدموية في الوريد، يمكن للجلطة في الشريان أن تسبب مشاكل</p><p dir="RTL">خطيرة. على سبيل المثال، يمكن أن تسبب نوبة قلبية أو سكتة دماغية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>العوامل التي تزيد من خطر حدوث جلطة دموية في الشريان</strong></p><p dir="RTL">من المهم ملاحظة أن خطر الإصابة بنوبة قلبية أو سكتة دماغية بسبب استخدام</p><p dir="RTL">ليندينيت صغير جدًا، ولكن يمكن أن يزيد:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مع زيادة العمر (بعد عمر 35 سنة تقريبا)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تدخنين. عند استخدام وسيلة منع حمل هرمونية مركبة مثل</p><p dir="RTL">ليندينيت، ينصح بالتوقف عن التدخين. إذا كنت غير قادرة على التوقف عن التدخين، وكان عمرك أكبر من 35 سنة، قد ينصحك طبيبك باستخدام نوع آخر من وسائل منع الحمل</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعانين من زيادة الوزن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابة بارتفاع ضغط الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تعرض أحد أفراد عائلتك المباشرة لنوبة قلبية أو سكتة دماغية في سن</p><p dir="RTL">مبكرة (أقل من 50 سنة تقريبا). في هذه الحالة، يمكن أيضًا أن يكون لديك خطر أعلى للإصابة بنوبة قلبية أو سكتة دماغية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت أنت أو أي من أفراد عائلتك المباشرة تعانون من ارتفاع نسبة الدهون في الدم (الكوليسترول أو الدهون الثلاثية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تصابين بالصداع النصفي، خاصة الصداع النصفي مع أورة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -إذا كان لديك مشكلة في القلب (اضطراب الصمامات أو اضطراب في الإيقاع يسمى (الرجفان الاذيني)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابة بمرض السكر</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تعانين من أكثر من واحدة من هذه الحالات أو إذا كان أي منها شديدًا بشكل خاص، فقد يزداد خطر الإصابة بجلطة دموية أكثر.</p><p dir="RTL">إذا تغيرت أي من الحالات المذكورة أعلاه أثناء استخدام ليندينيت، على سبيل المثال إذا بدأت في التدخين، أو إذا أصيب أحد أفراد الأسرة المقربين بجلطة بدون سبب معروف، أو إذا اكتسبت الكثير من الوزن، أخبري طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>2-4 حبوب منع الحمل والسرطان</strong></p><p dir="RTL">في حين أن الحبوب ذات الجرعة العالية تقلل من خطر الإصابة بسرطان المبيض والرحم إذا تم استخدامها على المدى الطويل، فإنه ليس من الواضح ما إذا كانت حبوب منع الحمل ذات الجرعة الأقل مثل ليندينيت تعطي نفس الآثار الوقائية أيضا.</p><p dir="RTL">ومع ذلك، يبدو أيضا أن تناول حبوب منع الحمل يزيد قليلا من خطر الإصابة بسرطان</p><p dir="RTL">عنق الرحم - على الرغم من أن هذا قد يكون بسبب ممارسة الجماع بدون واقي</p><p dir="RTL">ذكري، أكثر من كونه بسبب حبوب منع الحمل. يجب على جميع النساء إجراء</p><p dir="RTL">اختبارات فحص سرطان الرحم بانتظام.</p><p dir="RTL">إذا كنت مصابة بسرطان الثدي، أو كنت قد أصبت به في الماضي، يجب عليك</p><p dir="RTL">عدم تناول حبوب منع الحمل. حبوب منع الحمل تزيد قليلاً من خطر الإصابة بسرطان</p><p dir="RTL">الثدي. ويزداد هذا الخطر كلما استمريت في تناول حبوب منع الحمل لفترة أطول،</p><p dir="RTL">ولكنه يعود إلى وضعه الطبيعي خلال 10 سنوات تقريبًا من إيقافها. نظراً لأن</p><p dir="RTL">سرطان الثدي نادر في النساء تحت سن ال 40، فإن الحالات الإضافية للإصابة</p><p dir="RTL">بسرطان الثدي في مستخدمي حبوب منع الحمل الحالية والحديثة تكون صغيرة. على</p><p dir="RTL">سبيل المثال:</p><p dir="RTL">&nbsp;</p><p dir="RTL">-من بين 10,000 سيدة لم يتناولن حبوب منع الحمل أبدا، ستصاب 16 سيدة بسرطان الثدي عند سن 35 سنة.</p><p dir="RTL">-من بين 10,000 سيدة يتناولن حبوب منع الحمل لمدة 5 سنوات في أوائل العشرينات من العمر، ستصاب حوالي 17 - 18 سيدة بسرطان الثدي عند سن 35 سنة.</p><p dir="RTL">-من بين 10,000 سيدة لم يتناولن حبوب منع الحمل أبدا، ستصاب 100 سيدة بسرطان الثدي عند سن 45 سنة.</p><p dir="RTL">-من بين 10,000 سيدة يتناولن حبوب منع الحمل لمدة 5 سنوات في أوائل الثلاثينات من العمر، ستصاب حوالي 110 سيدة بسرطان الثدي عند سن 45 سنة.</p><p dir="RTL">يكون خطر إصابتك بسرطان الثدي أعلى:</p><p dir="RTL">-إذا كان لديك قريبة مقربة (أم أو أخت أو جدة) مصابة بسرطان الثدي</p><p dir="RTL">-إذا كنت تعانين من زيادة شديدة في الوزن</p><p dir="RTL">-راجعي الطبيب في أقرب وقت ممكن إذا لاحظت أي تغيرات في ثدييك، مثل ترصع في الجلد أو تغيرات في الحلمة أو أي كتل يمكنك رؤيتها أو الشعور بها.</p><p dir="RTL">-كما ارتبط تناول حبوب منع الحمل أيضاً بأمراض الكبد، مثل اليرقان وأورام الكبد غير</p><p dir="RTL">السرطانية، ولكن هذا نادر الحدوث. في حالات نادرة جدا، ارتبطت حبوب منع الحمل</p><p dir="RTL">أيضا ببعض أشكال سرطان الكبد في النساء اللاتي تناولنها لفترة طويلة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-راجعي الطبيب في أسرع وقت ممكن إذا عانيتِ من ألم شديد في معدتك أو اصفرار في البشرة أو العيون (يرقان). قد تحتاجين إلى التوقف عن تناول ليندينيت.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>5-2 اضطرابات نفسية</strong></p><p dir="RTL">بعض النساء اللاتي يستخدمن موانع الحمل الهرمونية بما في ذلك ليندينيت أبلغن عن عراض اكتئاب أو مزاج مكتئب. قد يكون الاكتئاب خطيرًا وقد يؤدي أحيانًا إلى أفكار انتحارية. إذا واجهتي تغيرات في المزاج أو أعراض اكتئاب، فاتصلي بطبيبك للحصول على مزيد من النصائح الطبية في أقرب وقت ممكن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>6-2 الأدوية الأخرى وليندينيت</strong></p><p dir="RTL">إذا احتجت في أي وقت إلى تناول دواء آخر في نفس الوقت الذي تتناولين فيه حبوب</p><p dir="RTL">منع الحمل، فأخبري طبيبك أو الصيدلي أو طبيب الأسنان دائمًا أنك تتناول ليندينيت.</p><p dir="RTL">تحققي أيضًا من النشرات التي تأتي مع جميع الأدوية الخاصة بك لمعرفة ما إذا كان</p><p dir="RTL">يمكن تناولها مع موانع الحمل الهرمونية.</p><p dir="RTL">قد يكون لبعض الأدوية تأثير على مستويات الدم في ليندينيت ويمكن أن تمنعها من</p><p dir="RTL">العمل بشكل صحيح - على سبيل المثال:</p><p dir="RTL">-بعض الأدوية المستخدمة في علاج الصرع</p><p dir="RTL">-بعض الأدوية المستخدمة لعلاج عدوى فيروس نقص المناعة البشرية والتهاب الكبد الوبائي سي (ما يسمى بمثبطات الأنزيم البروتيني ومثبطات</p><p dir="RTL">النسخ العكسي غير النوكليوزيدية)</p><p dir="RTL">-غريزيوفولفين (دواء مضاد للفطريات)</p><p dir="RTL">-بعض المضادات الحيوية</p><p dir="RTL">-بعض المهدئات (تسمى &laquo;الباربيتورات)&raquo;</p><p dir="RTL">-نبتة سانت جون (علاج عشبي)</p><p dir="RTL">إذا احتجت إلى تناول أحد هذه الأدوية، قد لا تكون ليندينيت مناسبة لك أو قد تحتاجين إلى استخدام وسائل منع حمل إضافية لفترة من الوقت. يمكن لطبيبك أو الصيدلي أو طبيب الأسنان إخبارك إذا كان ذلك ضروريًا وإلى متى.</p><p dir="RTL">يمكن أن يؤثر ليندينيت أيضًا على مدى جودة عمل الأدوية الأخرى. قد يحتاج طبيبك إلى تعديل جرعة دوائك الآخر.</p><p dir="RTL">بالإضافة إلى ذلك، يمكن أن تتداخل ليندينيت أيضًا مع نتائج بعض اختبارات الدم، لذلك أخبري طبيبك دائمًا أنك تتناولين ليندينيت إذا كان لديك فحص دم.</p><p dir="RTL">لا تستعملي ليندينيت إذا كنت تعانين من التهاب الكبد سي وتتناولين الأدوية التي تحتوي على أومبيتاسفير / باريتابريفير / ريتونافير وداسابوفير أو جليكابريفير /</p><p dir="RTL">بيبرنتاسفير لأن هذا قد يسبب زيادات في نتائج تحليل الدم لوظائف الكبد (زيادة في إنزيم ALT للكبد). سيصف لك طبيبك نوعًا آخر من وسائل منع الحمل قبل بدء العلاج بهذه الأدوية. يمكن إعادة ليندينيت مرة أخرى بعد حوالي أسبوعين من انتهاء العلاج. انظري قسم &laquo;(لا تستخدم ليندينيت)&raquo;</p><p dir="RTL"><strong>7-2 ليندينيت مع الطعام والشراب</strong></p><p dir="RTL">لا توجد تعليمات خاصة حول الطعام والشراب أثناء استخدام ليندينيت.</p><p dir="RTL"><strong>8-2 الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">لا يجب استعمال ليندينيت إذا كنت حاملا. إذا كنت تعتقدين أنك حاملاً، قومي بإجراء اختبار الحمل للتأكد من أنك حامل قبل أن تتوقفي عن تناول ليندينيت.</p><p dir="RTL">إذا كنت مرضعة، قد ينصحك طبيبك أو ممرضة تنظيم الأسرة بعدم تناول ليندينيت.</p><p dir="RTL">سيكونون قادرين على اقتراح وسائل منع الحمل البديلة. قد لا تمنعك الرضاعة الطبيعية من الحمل.</p><p dir="RTL"><strong>9-2 القيادة واستعمال الماكينات</strong></p><p dir="RTL">ليس ل ليندينيت أي تأثير معروف على القدرة على القيادة أو استعمال الماكينات</p><p dir="RTL"><strong>10-2 ليندينيت يحتوي على لاكتوز وسكروز</strong></p><p dir="RTL">إذا أخبرك طبيبك أنك لا تتحملي بعض السكريات، فاتصلي بطبيبك قبل استخدام ليندينيت</p><p dir="RTL">يحتوي هذا الدواء على أقل من 1 مليمول صوديوم (23 مجم) لكل قرص، وهذا يعني بشكل أساسي &laquo;خالٍ من الصوديوم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كيفية</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>ليندينيت</strong></p><p dir="RTL"><strong>&nbsp;1-3</strong><strong>كيفية تناولها</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لمنع الحمل، تناولي ليندينيت دائماً كما هو موضح أدناه. استشيري طبيبك أو ممرضة تنظيم الأسرة إذا لم تكوني متأكدة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناولي ليندينيت كل يوم لمدة 21 يوما</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تأتي ليندينيت في شرائط من 21 حبة، كل واحدة منها عليها علامة بيوم من أيام الأسبوع.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناولي حبة منع الحمل الخاصة بك في نفس الوقت كل يوم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ابدئي بتناول حبة منع الحمل التي تحمل اليوم الصحيح من الأسبوع.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اتبعي اتجاه الأسهم على الشريط. تناولي حبة واحدة كل يوم، حتى تنتهي من</p><p dir="RTL">تناول ال 21 حبة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ابتلعي كل حبة كاملة مع الماء إذا لزم الأمر. لا تمضغي الحبة. بعد ذلك تكون هناك سبعة أيام خالية من حبوب منع الحمل</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعد تناول جميع الحبوب ال 21 في الشريط، يكون لديك سبعة أيام لا تتناولي فيها</p><p dir="RTL">أي حبوب. لذا، إذا كنت قد تناولت آخر حبة في العبوة يوم الجمعة، فسوف تتناولين</p><p dir="RTL">أول حبة من عبوتك التالية يوم السبت من الأسبوع التالي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وفي غضون أيام قليلة من تناول آخر حبة في الشريط، يجب أن يكون لديك نزيف</p><p dir="RTL">انسحابي مثل الدورة الشهرية. قد لا يكون هذا النزيف قد توقف عندما يحين موعد</p><p dir="RTL">بدء شريطك التالي من الحبوب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تحتاجين إلى استخدام وسيلة منع حمل إضافية خلال هذه الأيام السبعة الخالية</p><p dir="RTL">من حبوب منع الحمل - طالما أنك قد أخذت حبوب منع الحمل بشكل صحيح وبدأت</p><p dir="RTL">الشريط التالي من الحبوب في الوقت المحدد. ثم ابدئي شريطك التالي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ابدئي بتناول شريطك التالي من ليندينيت بعد الأيام السبعة الخالية من الحبوب</p><p dir="RTL">حتى لو كنت لا تزالي تنزفين. ابدئي الشريط الجديد دائماً في الوقت المحدد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طالما أنك تتناولين ليندينيت بشكل صحيح، فستبدئين دائمًا كل شريط جديد في نفس اليوم من الأسبوع.</p><p dir="RTL"><strong>2-3 البدء في تناول ليندينيت</strong></p><p dir="RTL">كمستخدمة جديدة أو عند بدء حبوب منع الحمل مرة أخرى بعد فترة انقطاع من الأفضل تناول أول حبوب ليندينيت الخاصة بك في اليوم الأول من دورتك الشهرية التالية. إذا بدأت بهذه الطريقة، ستحصلين على حماية وسائل منع الحمل مع حبتك الأولى.</p><p dir="RTL"><strong><u>تغيير إلى ليندينيت من نوع آخر من حبوب منع الحمل</u></strong></p><p dir="RTL"><strong><u>إذا كنت حاليا تستخدمين حبوب منع الحمل ذو 21 يوما</u></strong><strong>:</strong> ابدئي في تناول ليندينيت في اليوم التالي لنهاية الشريط السابق. ستحصلين على حماية وسائل منع الحمل مع حبتك الأولي. لن يكون لديك نزف حتى إنتهاء الشريط الأول من ليندينيت.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong><u>إذا كنت حاليا تستخدمين حبوب منع الحمل ذو 28 يوما</u></strong>: ابدئي في تناول ليندينيت في اليوم التالي لتناولك آخر حبة فعالة. ستحصلين على حماية وسائل منع الحمل مع حبتك الأولي. لن يحدث لديك نزف حتى إنتهاء الشريط الأول من ليندينيت. أو، إذا كنت تتناولين حبوب منع الحمل التي تحتوي على بروجيستوجين فقط (POP أو &laquo;الحبة الصغيرة &raquo;): ابدئي في تناول ليندينيت في اليوم الأول من النزيف، حتى إذا كنت قد تناولت حبة منع الحمل المحتوية على بروجيستوجين فقط في ذلك اليوم. سيكون لديك غطاء مانع للحمل على الفور.</p><p dir="RTL"><strong><u>البدء في تناول ليندينيت بعد الإجهاض</u></strong></p><p dir="RTL">إذا حدث لديك إجهاض خلال الأشهر الثلاثة الأولى من الحمل، قد يطلب منك طبيبك البدء في تناول ليندينيت على الفور. وهذا يعني أنك ستحصلين على حماية وسائل منع الحمل مع حبتك الأولي.</p><p dir="RTL">إذا كان قد حدث لديك إجهاض بعد الشهر الثالث من الحمل، اطلبي من طبيبك</p><p dir="RTL">النصيحة. قد تحتاجين إلى استخدام وسائل منع حمل إضافية، مثل الواقي الذكري،</p><p dir="RTL">لفترة قصيرة.</p><p dir="RTL"><strong><u>منع الحمل بعد الولادة</u></strong></p><p dir="RTL">-إذا كنت قد أنجبت طفلا مؤخرا، قد ينصحك طبيبك بوجوب البدء في تناول ليندينيت</p><p dir="RTL">بعد 21 يومًا من الولادة شريطة أن تكوني تتحركين بشكل كامل. ليس عليك</p><p dir="RTL">الانتظار لفترة. سوف تحتاجين إلى استخدام وسيلة أخرى لمنع الحمل، مثل الواقي</p><p dir="RTL">الذكري، حتى تبدئي في تناول ليندينيت ولأول 7 أيام من تناول حبوب منع الحمل.</p><p dir="RTL"><strong>3-3 حبة منسية</strong></p><p dir="RTL">-إذا كنت متأخرة عن تناول الحبة لمدة أقل من 12 ساعة، تناوليها على الفور.</p><p dir="RTL">استمري في تناول حبوب منع الحمل الخاصة بك في الوقت المعتاد. وهذا قد يعني أن</p><p dir="RTL">تتناولي حبتين في يوم واحد. لا تقلقي &ndash; لن تقل حماية وسيلة منع الحمل الخاص</p><p dir="RTL">بك.</p><p dir="RTL">-إذا كنت متأخرة عن تناول الحبة لمدة أكثر من 12 ساعة، أو فاتتك أكثر من حبة</p><p dir="RTL">واحدة، فقد تقل حماية وسيلة منع الحمل.</p><p dir="RTL">-تناولي آخر حبة منع حمل منسية بمجرد تذكرك، حتى لو كان ذلك يعني</p><p dir="RTL">تناول حبتين في وقت واحد. اتركي أي حبوب منع حمل منسية في وقت سابق</p><p dir="RTL">في العبوة.</p><p dir="RTL">-استمري في تناول حبوب منع الحمل كل يوم للسبعة أيام التالية في</p><p dir="RTL">وقتك المعتاد.</p><p dir="RTL">-إذا وصلت إلى نهاية شريط الحبوب خلال هذه الأيام السبعة، ابدئي الشريط</p><p dir="RTL">التالي دون أخذ استراحة السبعة أيام المعتادة. على الأرجح لن يكون لديك</p><p dir="RTL">نزيف حتى تنتهي من الشريط الثاني من الحبوب، ولكن لا تقلقي. إذا انتهيت</p><p dir="RTL">من الشريط الثاني من الحبوب ولم يحدث لديك نزيف، قومي بإجراء اختبار</p><p dir="RTL">الحمل قبل بدء شريط آخر.</p><p dir="RTL">-استخدمي وسيلة منع حمل إضافية لمدة سبعة أيام بعد نسيان حبة منع الحمل، مثل الواقي الذكري.</p><p dir="RTL">-إذا كنت قد نسيت حبة واحدة أو أكثر من الأسبوع الأول من الشريط (الأيام</p><p dir="RTL">من 1 إلى 7) وكان قد حدث جماع في ذلك الأسبوع فقد تصبحين حاملاً.</p><p dir="RTL">اتصلي بطبيبك أو ممرضة تنظيم الأسرة أو الصيدلي للحصول على المشورة</p><p dir="RTL">بأسرع وقت. قد يوصونك باستخدام وسيلة منع حمل طارئة.</p><p dir="RTL">-إذا كنت قد نسيت أي من الحبوب في أحد الشرائط، ولم تنزفي في أول استراحة</p><p dir="RTL">خالية من حبوب منع الحمل، فقد تكونين حاملا. اتصلي بطبيبك أو عيادة</p><p dir="RTL">تنظيم الأسرة، أو قومي بإجراء اختبار الحمل بنفسك.</p><p dir="RTL">-إذا بدأت شريط جديد من الحبوب متأخرة، أو جعلت &laquo;أسبوع الإجازة&raquo; أطول من</p><p dir="RTL">سبعة أيام، فقد لا تكوني محمية من الحمل. إذا حدث جماع في السبعة أيام</p><p dir="RTL">السابقة، استشيري طبيبك أو ممرضة تنظيم الأسرة أو الصيدلي. قد تحتاجين إلى</p><p dir="RTL">التفكير في وسيلة منع حمل طارئة. ويجب عليك أيضًا استخدام وسيلة منع حمل</p><p dir="RTL">إضافية، مثل الواقي الذكري، لمدة سبعة أيام.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>4-3 حبة منع حمل مفقودة</strong></p><p dir="RTL">إذا فقدت حبة منع الحمل، إما أن تتناولي حبة منع الحمل الأخيرة من الشريط بدلا من حبة منع الحمل المفقودة. ثم تناولي جميع الحبوب الأخرى في أيامها المناسبة. ستكون دورتك أقصر</p><p dir="RTL">من المعتاد بيوم واحد، ولكن لن تتأثر حماية وسيلة منع الحمل الخاصة بك.</p><p dir="RTL">بعد السبعة أيام الخالية من حبوب منع الحمل سيكون لديك يوم بدء جديد، وسيكون قبل يوم واحد من ذي قبل.</p><p dir="RTL">أو إذا كنت لا ترغبين في تغيير يوم بدء دورتك، تناولي حبة من شريط احتياطي إذا</p><p dir="RTL">كان لديك واحد. ثم تناولي جميع الحبوب الأخرى من شريطك الحالي كالمعتاد. ثم</p><p dir="RTL">يمكنك الاحتفاظ بالشريط الاحتياطي المفتوح في حالة فقد أي حبوب أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>5-3 إذا شعرت بالغثيان أو الإسهال</strong></p><p dir="RTL">إذا شعرت بالغثيان (القيء) أو أصبت بإسهال شديد للغاية خلال 4 ساعات من</p><p dir="RTL">تناول الحبة، فقد لا يحصل جسمك على الجرعة المعتادة للهرمونات من تلك الحبة.</p><p dir="RTL">إذا أصبحت أفضل في غضون 12 ساعة من تناول ليندينيت، اتبعي التعليمات الواردة</p><p dir="RTL">في القسم 3.4 حبة منع حمل مفقودة، والتي تصف كيفية تناول حبة أخرى.</p><p dir="RTL">إذا كنت لا تزالين تشعرين بالغثيان أو كنت مصابة بالإسهال بعد مرور أكثر من 12</p><p dir="RTL">ساعة من تناول ليندينيت، راجعي القسم 3.3 ، حبة منسية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحدثي مع طبيبك إذا استمر اضطراب المعدة أو ازداد سوءا. فمن الممكن أن</p><p dir="RTL">يوصي لك بشكل آخر من أشكال وسائل منع الحمل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>6-3 افتقدت دورة شهرية &ndash; هل يمكن أن تكوني حاملا؟</strong></p><p dir="RTL">في بعض الأحيان، قد يغيب عنك النزيف الانسحابي. وقد يعني هذا أنك حامل،</p><p dir="RTL">ولكن هذا أمر مستبعد للغاية إذا كنت قد تناولت حبوبك بشكل صحيح. ابدئي</p><p dir="RTL">الشريط التالي في الوقت المعتاد. إذا كنت تعتقدين أنك ربما تكوني قد أصبحت</p><p dir="RTL">حاملا (على سبيل المثال، بسبب نسيان تناول الحبوب أو تناول أدوية أخرى)، أو إذا</p><p dir="RTL">افتقدت نزيف آخر (دورة شهرية ثانية)، فعليك إجراء اختبار الحمل. ويمكنك شراء</p><p dir="RTL">اختبار الحمل من الصيدلية أو إجراء اختبار مجاني في عيادة تنظيم الأسرة أو عند</p><p dir="RTL">الطبيب. إذا كنت حاملا، توقفي عن تناول ليندينيت وراجعي طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>7-3 تناول أكثر من واحدة من حبوب منع الحمل لا ينبغي أن يسبب أذى</strong></p><p dir="RTL">من غير المرجح أن تناول أكثر من واحدة من حبوب منع الحمل سوف يسبب لك أي</p><p dir="RTL">ضرر، ولكن قد تشعرين بالغثيان أو القيء أو النزف من المهبل. حتى الفتيات اللاتي لم يبدأن بعد في الحيض، ولكنهن تناولن هذا الدواء عن طريق الخطأ، قد يتعرضن</p><p dir="RTL">لمثل هذا النزيف. تحدثي مع طبيبك إذا كان لديك أي من هذه الأعراض.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>8-3 عندما تريدين الحمل</strong></p><p dir="RTL">إذا كنت تخططين للإنجاب، فمن الأفضل استخدام طريقة أخرى لمنع الحمل بعد</p><p dir="RTL">إيقاف ليندينيت حتى تحصلين على دورة مضبوطة. يعتمد طبيبك أو ممرضة التوليد</p><p dir="RTL">على تاريخ آخر دورة طبيعية لك لإخبارك عن موعد ولادة طفلك. ومع ذلك، فإنه لن</p><p dir="RTL">يسبب لك أو للطفل أي ضرر إذا أصبحت حاملا على الفور.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>- التأثيرات</strong><strong> </strong><strong>الجانبية</strong><strong> </strong><strong>المحتملة</strong></p><p dir="RTL">مثل جميع الأدوية، من الممكن أن تسبب ليندينيت آثارا جانبية، وإن لم تكن تصيب</p><p dir="RTL">الجميع. إذا أصبت بأي من الآثار الجانبية، لا سيما إذا كانت شديدة ومستمرة، أو</p><p dir="RTL">شعرت بأي تغيير في صحتك والذي تعتقدين أنه قد يكون بسبب ليندينيت، يرجى</p><p dir="RTL">التحدث إلى طبيبك.</p><p dir="RTL">زيادة خطر حدوث جلطات دموية في الأوردة (الجلطات الدموية الوريدية (VTE)) أو</p><p dir="RTL">جلطات دموية في الشرايين (الجلطات الدموية الشريانية (ATE)) في جميع النساء</p><p dir="RTL">اللاتي يتناولن وسائل منع حمل هرمونية مركبة. للمزيد من المعلومات عن المخاطر</p><p dir="RTL">المختلفة الناجمة عن تناول وسائل منع الحمل الهرمونية المركبة، يرجى مراجعة</p><p dir="RTL">القسم &laquo; 2 ما تحتاجين إلى معرفته قبل تناول ليندينيت.&raquo;</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبري طبيبك أو الصيدلي أو ممرضة تنظيم الأسرة إذا انتابك القلق بشأن</p><p dir="RTL">أي آثار جانبية تعتقدين أنها قد تكون بسبب ليندينيت.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>2-4 آثار جانبية أقل خطورة</strong></p><p dir="RTL">آثار جانبية شائعة (بين 100 و1000 من بين كل 10000 مستخدمة قد تتأثر)</p><p dir="RTL">-الغثيان (الشعور بالإعياء)</p><p dir="RTL">-ألم في المعدة</p><p dir="RTL">-اكتساب الوزن</p><p dir="RTL">-صداع</p><p dir="RTL">-أمزجة اكتئابية أو تقلب المزاج</p><p dir="RTL">-قرحة أو ألم في الثدي</p><p dir="RTL"><strong>-آثار جانبية غير شائعة (بين 10 و 100 من بين كل 10000 مستخدمة قد تتأثر)</strong></p><p dir="RTL">-الشعور بالغثيان واضطرابات في المعدة</p><p dir="RTL">-احتباس السوائل</p><p dir="RTL">-صداع نصفي</p><p dir="RTL">-فقدان الاهتمام بالجنس</p><p dir="RTL">-تضخم الثدي</p><p dir="RTL">-طفح الجلدي، قد يسبب الحكة</p><p dir="RTL"><strong>-آثار جانبية نادرة (بين 1 و 10 من بين كل 10000 مستخدمة قد تتأثر)</strong></p><p dir="RTL">-تحمل ضعيف للعدسات اللاصقة</p><p dir="RTL">-زيادة الاهتمام بالجنس</p><p dir="RTL">-إفرازات من المهبل أو الثدي</p><p dir="RTL"><strong>آثار جانبية أخرى تم الإبلاغ عنها</strong></p><p dir="RTL">-قد يحدث نزيف وتبقيع بين الدورات في بعض الأحيان خلال الأشهر القليلة</p><p dir="RTL">الأولى، ولكن عادة ما يتوقف هذا بمجرد تكيف جسمك مع ليندينيت. إذا استمر</p><p dir="RTL">الأمر أو أصبح أكثر أو بدأ من جديد، اتصلي بطبيبك (انظري قسم 4.3)</p><p dir="RTL">-كلف (بقع بنية صفراء على الجلد). قد يحدث هذا حتى لو كنت تستخدمين</p><p dir="RTL">منذ عدة أشهر. ومن الممكن تقليل الكلف عن طريق تجنب التعرض</p><p dir="RTL">للكثير من ضوء الشمس و / أو مصابيح الأشعة فوق البنفسجية</p><p dir="RTL">-حدوث أو تدهور في اضطراب الحركة الرقاص</p><p dir="RTL">-التهاب القولون التقرحي</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحالات التي قد تتفاقم أثناء الحمل أو الاستخدام السابق للحبوب:</strong></p><p dir="RTL">-اصفرار الجلد (اليرقان)</p><p dir="RTL">-حكة مستمرة (حكة)</p><p dir="RTL">-مشاكل في الكلي أو الكبد</p><p dir="RTL">-حصى في المرارة</p><p dir="RTL">-بعض الحالات الطبية النادرة مثل الذئبة الحمامية الجهازية</p><p dir="RTL">-طفح جلدي مثل النفطة (هربس الحمل) أثناء الحمل</p><p dir="RTL">-شكل من أشكال الصمم الوراثي (تصلب الأذن)</p><p dir="RTL">-مرض كرون</p><p dir="RTL">-تاريخ شخصي أو عائلي لشكل من أشكال مرض الخلية المنجلية</p><p dir="RTL">-تورم في أجزاء الجسم (وذمة وعائية وراثية)</p><p dir="RTL">-مرض وراثي يسمى البورفيريا</p><p dir="RTL">-سرطان عنق الرحم</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبري طبيبك أو الصيدلي أو ممرضة تنظيم الأسرة إذا انتابك القلق بشأن</p><p dir="RTL">أي آثار جانبية تعتقدين أنها قد تكون بسبب ليندينيت. أخبريهم أيضا إذا أصبحت</p><p dir="RTL">أي من الحالات الموجودة أسوأ أثناء تناول ليندينيت.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>3-4 النزيف بين الدورات يجب ألا يستمر طويلاً</strong></p><p dir="RTL">قد يحدث لدى عدد قليل من النساء نزيف أو تبقيع غير متوقع أثناء تناولهن ليندينيت،</p><p dir="RTL">خاصة خلال الأشهر القليلة الأولى. ومن الطبيعي ألا يدعو هذا النزيف للقلق وسوف</p><p dir="RTL">يتوقف خلال يوم أو يومين. استمري في تناول ليندينيت كالمعتاد. يجب أن تختفي هذه</p><p dir="RTL">المشكلة بعد الشرائط القليلة الأولى.</p><p dir="RTL">كما قد يحدث لديك أيضًا نزيف غير متوقع إذا كنت لا تتناولين حبوب منع الحمل</p><p dir="RTL">بانتظام، لذا حاولي أن تتناولي حبوب منع الحمل في نفس الوقت كل يوم. وأيضا،</p><p dir="RTL">يمكن أن يحدث نزيف غير متوقع في بعض الأحيان بسبب أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">حددي موعد لرؤية طبيبك إذا حدث لديك نزيف اختراقي أو تبقيع:</p><p dir="RTL">استمر لأكثر من الأشهر القليلة الأولى</p><p dir="RTL">بدأ بعد استمرارك في تناول ليندينيت لبعض الوقت</p><p dir="RTL">استمر حتى بعد أن توقفتِ عن تناول ليندينيت.</p><p dir="RTL"><strong>الإبلاغ</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>التأثيرات</strong><strong> </strong><strong>الجانبية.</strong></p><p dir="RTL">إذا حدث لك أية تأثيرات جانبية فيجب إبلاغ الطبيب أو الصيدلي بها. وهذا يشمل أي تأثيرات جانبية محتملة لم يرد ذكرها في هذه النشرة. كما يمكن الإبلاغ عن التأثيرات الجانبية مباشرة عبر نظام الإبلاغ الوطني المشار إليه في الأسفل. بإبلاغك عن التأثيرات الجانبية فإنك تساعد في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL"><strong>المملكة العربية السعودية</strong>:</p><p dir="RTL"><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_2" o:spid="_x0000_s1026"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:7.2pt;margin-top:3.15pt;width:409.2pt;height:129pt;z-index:251657728;
 visibility:visible;mso-width-relative:margin;mso-height-relative:margin'
 o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF
90jcwfIWJU67QAgl6YK0S0CoHGBkTxKLZGx5TGhvj5O2G0SRWNoz/78nu9wcxkFMGNg6quQqL6RA
0s5Y6ir5vt9lD1JwBDIwOMJKHpHlpr69KfdHjyxSmriSfYz+USnWPY7AufNIadK6MEJMx9ApD/oD
OlTrorhX2lFEilmcO2RdNtjC5xDF9pCuTyYBB5bi6bQ4syoJ3g9WQ0ymaiLzg5KdCXlKLjvcW893
SUOqXwnz5DrgnHtJTxOsQfEKIT7DmDSUCaxw7Rqn8787ZsmRM9e2VmPeBN4uqYvTtW7jvijg9N/y
JsXecLq0q+WD6m8AAAD//wMAUEsDBBQABgAIAAAAIQA4/SH/1gAAAJQBAAALAAAAX3JlbHMvLnJl
bHOkkMFqwzAMhu+DvYPRfXGawxijTi+j0GvpHsDYimMaW0Yy2fr2M4PBMnrbUb/Q94l/f/hMi1qR
JVI2sOt6UJgd+ZiDgffL8ekFlFSbvV0oo4EbChzGx4f9GRdb25HMsYhqlCwG5lrLq9biZkxWOiqY
22YiTra2kYMu1l1tQD30/bPm3wwYN0x18gb45AdQl1tp5j/sFB2T0FQ7R0nTNEV3j6o9feQzro1i
OWA14Fm+Q8a1a8+Bvu/d/dMb2JY5uiPbhG/ktn4cqGU/er3pcvwCAAD//wMAUEsDBBQABgAIAAAA
IQBqZ65MKgIAAFEEAAAOAAAAZHJzL2Uyb0RvYy54bWysVNuO2yAQfa/Uf0C8N3auTaw4q222qSpt
L9JuPwBjHKMCQ4HETr9+B5xNo237UtUPiGGGw5kzM17f9FqRo3BeginpeJRTIgyHWpp9Sb897t4s
KfGBmZopMKKkJ+Hpzeb1q3VnCzGBFlQtHEEQ44vOlrQNwRZZ5nkrNPMjsMKgswGnWUDT7bPasQ7R
tcomeb7IOnC1dcCF93h6NzjpJuE3jeDhS9N4EYgqKXILaXVpreKabdas2DtmW8nPNNg/sNBMGnz0
AnXHAiMHJ3+D0pI78NCEEQedQdNILlIOmM04f5HNQ8usSLmgON5eZPL/D5Z/Pn51RNYlnVJimMYS
PYo+kHfQk0lUp7O+wKAHi2Ghx2OscsrU23vg3z0xsG2Z2Ytb56BrBauR3TjezK6uDjg+glTdJ6jx
GXYIkID6xukoHYpBEB2rdLpUJlLheLhYzKf5Cily9I0X0+U0T7XLWPF83TofPgjQJG5K6rD0CZ4d
732IdFjxHBJf86BkvZNKJcPtq61y5MiwTXbpSxm8CFOGdCVdzSfzQYG/QuTp+xOElgH7XUld0uUl
iBVRt/emTt0YmFTDHikrcxYyajeoGPqqPxemgvqEkjoY+hrnEDctuJ+UdNjTJfU/DswJStRHg2VZ
jWezOATJmM3fTtBw157q2sMMR6iSBkqG7TYMg3OwTu5bfGloBAO3WMpGJpFjzQdWZ97Yt0n784zF
wbi2U9SvP8HmCQAA//8DAFBLAwQUAAYACAAAACEATJtnDOEAAAAKAQAADwAAAGRycy9kb3ducmV2
LnhtbEyPy07DMBBF90j8gzVIbFDrNCUhDZlUCAlEd9BWsHXjaRLhR7DdNPw9ZgXL0Rzde261nrRi
IznfW4OwmCfAyDRW9qZF2O+eZgUwH4SRQllDCN/kYV1fXlSilPZs3mjchpbFEONLgdCFMJSc+6Yj
LfzcDmTi72idFiGeruXSiXMM14qnSZJzLXoTGzox0GNHzef2pBGK25fxw2+Wr+9NflSrcHM3Pn85
xOur6eEeWKAp/MHwqx/VoY5OB3sy0jOFMCuyNKIIWRonRGCVpxmwA8JykRTA64r/n1D/AAAA//8D
AFBLAQItABQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAAAAAAAAAAAAAAAAAAABbQ29udGVudF9U
eXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhADj9If/WAAAAlAEAAAsAAAAAAAAAAAAAAAAALwEAAF9y
ZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAGpnrkwqAgAAUQQAAA4AAAAAAAAAAAAAAAAALgIAAGRy
cy9lMm9Eb2MueG1sUEsBAi0AFAAGAAgAAAAhAEybZwzhAAAACgEAAA8AAAAAAAAAAAAAAAAAhAQA
AGRycy9kb3ducmV2LnhtbFBLBQYAAAAABAAEAPMAAACSBQAAAAA=
"/><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p dir="RTL">المركز الوطني للتيقظ&nbsp;الدوائي</p><p dir="RTL">الهاتف الموحد: 19999</p><p dir="RTL">البريد الالكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الإلكتروني: www.sfda.gov.sa</p></td></tr></tbody></table></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>دول الخليج الأخرى: </strong></p><p dir="RTL"><strong>الرجاء الإتصال بالمؤسسات والهيئات الوطنية لكل دولة.</strong></p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كيفية</strong><strong> </strong><strong>تخزين</strong><strong> </strong><strong>ليندينيت.</strong></p><p dir="RTL">احتفظ بهذا الدواء بعيدًا عن متناول الأطفال.</p><p dir="RTL">لا تستعملي ليندينيت بعد انتهاء مدة صلاحيته المدونة على الشريط أو العبوة. يشير تاريخ الانتهاء إلى آخر يوم في ذلك الشهر.</p><p dir="RTL">يجب حفظ الدواء في درجة حرارة لا ترتفع عن 30 درجة مئوية &nbsp;في عبوته الأصلية كما يجب حمايته من أشعة الشمس والرطوبة.</p><p dir="RTL">يجب عدم التخلص من أية أدوية بإلقائها في شبكة الصرف الصحي) المجاري) أو القمامة المنزلية. ويجب سؤال الطبيب أو الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستعملها. فهذه الإجراءات ستساعد في حماية البيئة.</p><p dir="RTL">يجب حفظ المنتج في درجة حراره لاترتفع عن 30 درجة مئوية&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</p><p dir="RTL"><strong>على</strong><strong> </strong><strong>ماذا</strong><strong> </strong><strong>يحتوي</strong><strong> </strong><strong>ليندينيت</strong><strong> </strong><strong>؟</strong></p><p dir="RTL">&nbsp;- المواد الفعالة هي 75 مكيروجرام من جيستودين و 30 ميكروجرام من اثنيل استراديول في كل قرص مغلف.</p><p dir="RTL">&nbsp;- المكونات الأخرى هي اديتات الكالسيوم، استيارات المغناسيوم، السليكا الغروية غير المائية، بروفيدون، ونشاء الذرة، لاكتوز أحادي مائي، أصفر &quot;كينولينE 104 ، ثاني أكسيد التيتانيوم، ماكروجول 6000 ، تالك، كربونات الكالسيوم، سكروز.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما</strong><strong> </strong><strong>هو</strong><strong> </strong><strong>شكل</strong><strong> </strong><strong>ليندينيت</strong><strong> </strong><strong>وما</strong><strong> </strong><strong>هي</strong><strong> </strong><strong>محتويات</strong><strong> </strong><strong>العبوة.</strong></p><p dir="RTL">أقراص مغلفة : صفراء مستديرة محدبة الوجهين بغلاف سكري وكلا الوجهين بدون طباعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>العبوات</strong><strong>:</strong></p><p dir="RTL">21 قرص في شريط من البلاستيك داخل علبة كرتون.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الصانع:</strong></p><p dir="RTL">شركة ريكتار بي ال سي</p><p dir="RTL">اتش- 1103 بودابست</p><p dir="RTL">جيومروي يو تي 19-21&nbsp;&nbsp;&nbsp; &nbsp;</p><p dir="RTL">المجر</p><p dir="RTL">للاستعلام والحصول على أي معلومات حول هذا المنتج الدوائي يرجى الإيصال بممثلنا المحلي <strong>حامل</strong><strong> </strong><strong>ترخيص</strong><strong> </strong><strong>التسويق</strong><strong>:</strong></p><p dir="RTL">شركة آجا للصناعات الصيدلانية</p><p dir="RTL">المدينة الصناعية، حائل، المملكة العربية السعودية</p><p dir="RTL">هاتف:&nbsp; 00966165715075&nbsp;&nbsp; &nbsp;</p><p dir="RTL">فاكس: 00966165715071&nbsp;&nbsp; &nbsp;</p><p dir="RTL">ص.ب: 6979&nbsp;</p><p dir="RTL">الرمز البريدي : 55414 &nbsp;&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم اعتماد هذه النشرة آخر مرة بتاريخ 11/2023
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lindynette 75 micrograms / 30 micrograms coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                75 micrograms of gestodene and 30 micrograms of ethinylestradiol in each coated tablet.

Excipients with known effect: each tablet contains 37.16 mg lactose monohydrate and 19.66 mg sucrose.
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Yellow, round, biconvex sugar-coated tablets. The breaking surface is white.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Oral contraception.</p><p>The decision to prescribe Lindynette should take into consideration the individual woman&rsquo;s current risk factors, particularly those for venous thromboembolism (VTE), and how the risk of VTE with Lindynette compares with other combined hormonal contraceptives (see sections 4.3 and 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>First treatment cycle:</u> 1 tablet daily for 21 days, starting on the first day of the menstrual cycle. Contraceptive protection begins immediately.</p><p><u>Subsequent cycles:</u> Tablet taking from the next pack of Lindynette is continued after a 7-day interval, beginning on the same day of the week as the first pack.</p><p><strong><u>Changing from 21-day combined oral contraceptives:</u> </strong>The first tablet of Lindynette should be taken on the first day immediately after the end of the previous oral contraceptive course. Additional contraceptive precautions are not required.</p><p><strong><u>Changing from a combined Every Day pill (28 day tablets):</u></strong></p><p>Lindynette should be started after taking the last active tablet from the Every Day Pill pack. The first Lindynette tablet is taken the next day. Additional contraceptive precautions are not then required.</p><p><strong><u>Changing from a progestogen-only pill (POP):</u></strong></p><p>The first tablet of Lindynette should be taken on the first day of bleeding, even if a POP has already been taken on that day. Additional contraceptive precautions are not then required. The remaining progestogen-only pills should be discarded.</p><p><strong><u>Post-partum and post-abortum use:</u></strong></p><p>After pregnancy, oral contraception can be started 21 days after a vaginal delivery, provided that the patient is fully ambulant and there are no puerperal complications. Additional contraceptive precautions will be required for the first 7 days of tablet taking. Since the first post-partum ovulation may precede the first bleeding, another method of contraception should be used in the interval between</p><p>&nbsp;</p><p>&nbsp;</p><p>OGY&Eacute;I/33097/2021</p><p>&nbsp;</p><p>childbirth and the first course of tablets. After a first-trimester abortion, oral contraception may be started immediately in which case no additional contraceptive precautions are required.</p><p>Special circumstances requiring additional contraception</p><p><u>Incorrect administration</u>: A single delayed tablet should be taken as soon as possible, and if this can be done within 12 hours of the correct time, contraceptive protection is maintained. With longer delays, additional contraception is needed. Only the most recently delayed tablet should be taken, earlier missed tablets being omitted, and additional non-hormonal methods of contraception (except the rhythm or temperature methods) should be used for the next 7 days, while the next 7 tablets are being taken. Additionally, therefore, if tablet(s) have been missed during the last 7 days of a pack, there should be no break before the next pack is started. In this situation, a withdrawal bleed should not be expected until the end of the second pack. Some breakthrough bleeding may occur on tablet taking days but this is not clinically significant. If the patient does not have a withdrawal bleed during the tablet-free interval following the end of the second pack, the possibility of pregnancy must be ruled out before starting the next pack.</p><p><u>Gastro</u>-<u>intestinal upset</u>: Vomiting or diarrhoea may reduce the efficacy of oral contraceptives by preventing full absorption. If vomiting or diarrhoea occurs within 4 hours of taking Lindynette tablet- taking from the current pack should be continued. Additional non-hormonal methods of contraception (except the rhythm or temperature methods) should be used during the gastro-intestinal upset and for 7 days following the upset.</p><p>If these 7 days overrun the end of a pack, the next pack should be started without a break. In this situation, a withdrawal bleed should not be expected until the end of the second pack. If the patient does not have a withdrawal bleed during the tablet-free interval following the end of the second pack, the possibility of pregnancy must be ruled out before starting the next pack. Other methods of contraception should be considered if the gastro-intestinal disorder is likely to be prolonged.</p><p>&nbsp;</p><p><u>Children</u>: Not applicable.</p><p>&nbsp;</p><p><u>Elderly</u>: Not applicable.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Combined hormonal contraceptives (CHCs) should not be used in the following conditions. Should any of the conditions appear for the first time during use, the product should be stopped immediately.
-	Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.
-	Presence or risk of venous thromboembolism (VTE)
-	Venous thromboembolism – current VTE (on anticoagulants) or history of (e.g. deep venous thrombosis [DVT] or pulmonary embolism [PE]).
-	Known hereditary or acquired predisposition for venous thromboembolism, such as APC- resistance (including Factor V Leiden), antithrombin-III-deficiency, protein C deficiency, protein S deficiency.
-	Major surgery with prolonged immobilisation (see section 4.4).
-	A high risk of venous thromboembolism due to the presence of multiple risk factors (see section 4.4).
-	Presence or risk of arterial thromboembolism (ATE)
-	Arterial thromboembolism – current arterial thromboembolism, history of arterial thromboembolism (e.g. myocardial infarction) or prodromal condition (e.g. angina pectoris).
-	Cerebrovascular disease – current stroke, history of stroke or prodromal condition (e.g. transient ischaemic attack, TIA).
 
-	Known hereditary or acquired predisposition for arterial thromboembolism, such as hyperhomocysteinaemia and antiphospholipid-antibodies (anticardiolipin-antibodies, lupus anticoagulant).
-	History of migraine with focal neurological symptoms.
-	A high risk of arterial thromboembolism due to multiple risk factors (see section 4.4) or to the presence of one serious risk factor such as:
-	diabetes mellitus with vascular symptoms
-	severe hypertension
-	severe dyslipoproteinaemia
-	Presence or history of pancreatitis associated with severe hypertriglyceridaemia.
-	Presence or history of serious hepatic disorders (with acute liver dysfunctions).
-	Presence or history of liver tumours (benign or malignant).
-	Known or suspected sex-steroid influenced malignancies (e.g. of the genital organs or the breasts).
-	Undiagnosed abnormal vaginal bleeding.

Lindynette is contraindicated for concomitant use with the medicinal products containing ombitasvir/paritaprevir/ritonavir and dasabuvir or medicinal products containing glecaprevir/pibrentasvir (see sections 4.4 and 4.5).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Warnings</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If any of the conditions or risk factors mentioned below is present, the suitability of Lindynette should be discussed with the woman.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In the event of aggravation, or first appearance of any of these conditions or risk factors, the woman should be advised to contact her doctor to determine whether the use of Lindynette should be discontinued.</p><p><u>Risk of venous thromboembolism (VTE)</u></p><p>The use of any combined hormonal contraceptive (CHC) increases the risk of venous thromboembolism (VTE) compared with no use. Products that contain levonorgestrel, norgestimate or norethisterone are associated with the lowest risk of VTE. Other products such as Lindynette may have up to twice this level of risk. The decision to use any product other than one with the lowest VTE risk should be taken only after a discussion with the woman to ensure she understands the risk of VTE with Lindynette, how her current risk factors influence this risk, and that her VTE risk is highest in the first ever year of use. There is also some evidence that the risk is increased when a CHC is re-started after a break in use of 4 weeks or more.</p><p>In women who do not use a CHC and are not pregnant, about 2 out of 10,000 will develop a VTE over the period of one year. However, in any individual woman the risk may be far higher, depending on her underlying risk factors (see below).</p><p>It is estimated1 that out of 10,000 women who use a CHC containing gestodene between 9 and 12 women will develop a VTE in one year; this compares with about 62 in women who use a levonorgestrel-containing CHC.</p><p>In both cases, the number of VTEs per year is fewer than the number expected during pregnancy or in the postpartum period.</p><p>VTE may be fatal in 1-2% of cases.</p><p>&nbsp;</p><p>Number of VTE events per 10,000 women in one year</p><p><img src="data:image/png;base64,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" alt="" width="977" height="550" vspace="0" hspace="0" border="0" style="width:977px;height:550px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>Extremely rarely, thrombosis has been reported to occur in CHC users in other blood vessels,</p><p>e.g. hepatic, mesenteric, renal, cerebral or retinal veins and arteries.</p><p>Risk factors for VTE</p><p>The risk for venous thromboembolic complications in CHC users may increase substantially in a woman with additional risk factors, particularly if there are multiple risk factors (see table).</p><p>Lindynette is contraindicated if a woman has multiple risk factors that put her at high risk of venous thrombosis (see section 4.3). If a woman has more than one risk factor, it is possible that the increase in risk is greater than the sum of the individual factors &ndash; in this case her total risk of VTE should be considered. If the balance of benefits and risks is considered to be negative a CHC should not be prescribed (see section 4.3).</p><p>Table: Risk factors for VTE</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Risk factor</strong></p></td><td style="vertical-align:top"><p><strong>Comment</strong></p></td></tr><tr><td style="vertical-align:top"><p>Obesity (body mass index over 30&nbsp;kg/m&sup2;).</p></td><td style="vertical-align:top"><p>Risk increases substantially as BMI rises.</p><p>Particularly important to consider if other risk factors also present.</p></td></tr><tr><td style="vertical-align:top"><p>Prolonged immobilisation, major surgery, any surgery to the legs or pelvis, neurosurgery, or major trauma.</p><p>&nbsp;</p><p>Note: temporary immobilisation including air travel &gt;&nbsp;4&nbsp;hours can also be a risk factor for VTE, particularly in women with other risk factors.</p></td><td style="vertical-align:top"><p>In these situations it is advisable to discontinue use of the patch/pill/ring (in the case of elective surgery at least four weeks in advance) and not resume until two weeks after complete remobilisation. Another method of contraception should be used to avoid unintentional pregnancy.</p><p>Antithrombotic treatment should be considered if Lindynette has not been discontinued in advance.</p></td></tr><tr><td style="vertical-align:top"><p>Positive family history (venous thromboembolism ever in a sibling or parent especially at a relatively early age e.g. before 50).</p></td><td style="vertical-align:top"><p>If a hereditary predisposition is suspected, the woman should be referred to a specialist for advice before deciding about any CHC use.</p></td></tr><tr><td style="vertical-align:top"><p>Other medical conditions associated with VTE.</p></td><td style="vertical-align:top"><p>Cancer, systemic lupus erythematosus, haemolytic uraemic syndrome, chronic inflammatory bowel disease (Crohn&rsquo;s disease or ulcerative colitis) and sickle cell disease.</p></td></tr><tr><td style="vertical-align:top"><p>Increasing age.</p></td><td style="vertical-align:top"><p>Particularly above 35&nbsp;years.</p></td></tr></tbody></table><p>There is no consensus about the possible role of varicose veins and superficial thrombophlebitis in the onset or progression of venous thrombosis.</p><p>The increased risk of thromboembolism in pregnancy, and particularly the 6 week period of the puerperium, must be considered (for information on &ldquo;Pregnancy and lactation&rdquo; see Section 4.6).</p><p>Symptoms of VTE (deep vein thrombosis and pulmonary embolism)</p><p>In the event of symptoms women should be advised to seek urgent medical attention and to inform the healthcare professional that she is taking a CHC.</p><p>Symptoms of deep vein thrombosis (DVT) can include:</p><p>-&nbsp;&nbsp; unilateral swelling of the leg and/or foot or along a vein in the leg;</p><p>-&nbsp;&nbsp; pain or tenderness in the leg which may be felt only when standing or walking,</p><p>-&nbsp;&nbsp; increased warmth in the affected leg; red or discoloured skin on the leg.</p><p>Symptoms of pulmonary embolism (PE) can include:</p><p>-&nbsp;&nbsp; sudden onset of unexplained shortness of breath or rapid breathing;</p><p>-&nbsp;&nbsp; sudden coughing which may be associated with haemoptysis;</p><p>-&nbsp;&nbsp; sharp chest pain;</p><p>-&nbsp;&nbsp; severe light headedness or dizziness;</p><p>-&nbsp;&nbsp; rapid or irregular heartbeat.</p><p>Some of these symptoms (e.g. &ldquo;shortness of breath&rdquo;, &ldquo;coughing&rdquo;) are non-specific and might be misinterpreted as more common or less severe events (e.g. respiratory tract infections).</p><p><strong>Other signs of vascular occlusion can include: </strong>sudden pain, swelling and slight blue discoloration of an extremity.</p><p>If the occlusion occurs in the eye symptoms can range from painless blurring of vision which can progress to loss of vision. Sometimes loss of vision can occur almost immediately.</p><p>Risk of arterial thromboembolism (ATE)</p><p>Epidemiological studies have associated the use of CHCs with an increased risk for arterial thromboembolism (myocardial infarction) or for cerebrovascular accident (e.g. transient ischaemic attack, stroke). Arterial thromboembolic events may be fatal.</p><p>Risk factors for ATE</p><p>The risk of arterial thromboembolic complications or of a cerebrovascular accident in CHC users increases in women with risk factors (see table). Lindynette is contraindicated if a woman has one serious or multiple risk factors for ATE that puts her at high risk of arterial thrombosis (see section 4.3). If a woman has more than one risk factor, it is possible that the increase in risk is greater than the sum of the individual factors - in this case her total risk should be considered. If the balance of benefits and risks is considered to be negative a CHC should not be prescribed (see section 4.3).</p><p>&nbsp;</p><p>Table: Risk factors for ATE</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Risk factor</strong></p></td><td style="vertical-align:top"><p><strong>Comment</strong></p></td></tr><tr><td style="vertical-align:top"><p>Increasing age.</p></td><td style="vertical-align:top"><p>Particularly above 35&nbsp;years.</p></td></tr><tr><td style="vertical-align:top"><p>Smoking</p></td><td style="vertical-align:top"><p>Women should be advised not to smoke if they wish to use a CHC. Women over 35 who continue to smoke should be strongly advised to use a different method of contraception.</p></td></tr><tr><td style="vertical-align:top"><p>Hypertension</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Obesity (body mass index over 30&nbsp;kg/m<sup>2</sup>).</p></td><td style="vertical-align:top"><p>Risk increases substantially as BMI increases.</p><p>Particularly important in women with additional risk factors.</p></td></tr><tr><td style="vertical-align:top"><p>Positive family history (arterial thromboembolism ever in a sibling or parent especially at relatively early age e.g. below 50).</p></td><td style="vertical-align:top"><p>If a hereditary predisposition is suspected, the woman should be referred to a specialist for advice before deciding about any CHC use.</p></td></tr><tr><td style="vertical-align:top"><p>Migraine</p></td><td style="vertical-align:top"><p>An increase in frequency or severity of migraine during CHC use (which may be prodromal of a cerebrovascular event) may be a reason for immediate discontinuation.</p></td></tr><tr><td style="vertical-align:top"><p>Other medical conditions associated with adverse vascular events.</p></td><td style="vertical-align:top"><p>Diabetes mellitus, hyperhomocysteinaemia, valvular heart disease and atrial fibrillation, dyslipoproteinaemia and systemic lupus erythematosus.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Symptoms of ATE</strong></p><p>In the event of symptoms women should be advised to seek urgent medical attention and to inform the healthcare professional that she is taking a CHC.</p><p><u>Symptoms of a cerebrovascular accident can include:</u></p><p>-&nbsp;&nbsp; sudden numbness or weakness of the face, arm or leg, especially on one side of the body;</p><p>-&nbsp;&nbsp; sudden trouble walking, dizziness, loss of balance or coordination;</p><p>-&nbsp;&nbsp; sudden confusion, trouble speaking or understanding;</p><p>-&nbsp;&nbsp; sudden trouble seeing in one or both eyes;</p><p>-&nbsp;&nbsp; sudden, severe or prolonged headache with no known cause;</p><p>-&nbsp;&nbsp; loss of consciousness or fainting with or without seizure.</p><p>Temporary symptoms suggest the event is a transient ischaemic attack (TIA). <u>Symptoms of myocardial infarction (MI) can include:</u></p><p>-&nbsp;&nbsp; pain, discomfort, pressure, heaviness, sensation of squeezing or fullness in the chest, arm, or below the breastbone;</p><p>-&nbsp;&nbsp; discomfort radiating to the back, jaw, throat, arm, stomach;</p><p>-&nbsp;&nbsp; feeling of being full, having indigestion or choking;</p><p>-&nbsp;&nbsp; sweating, nausea, vomiting or dizziness;</p><p>-&nbsp;&nbsp; extreme weakness, anxiety, or shortness of breath;</p><p>-&nbsp;&nbsp; rapid or irregular heartbeats.</p><p>&nbsp;</p><p>Medical Examination/Consultation</p><p>Prior to the initiation or reinstitution of Lindynette a complete medical history (including family history) should be taken and pregnancy must be ruled out. Blood pressure should be measured and a physical examination should be performed, guided by the contra-indications (see section 4.3) and warnings (see section 4.4). It is important to draw a woman&rsquo;s attention to the information on venous and arterial thrombosis, including the risk of Lindynette compared with other CHCs, the symptoms of VTE and ATE, the known risk factors and what to do in the event of a suspected thrombosis.</p><p>The woman should also be instructed to carefully read the user leaflet and to adhere to the advice given. The frequency and nature of examinations should be based on established practice guidelines and be adapted to the individual woman.</p><p>Women should be advised that hormonal contraceptives do not protect against HIV infections (AIDS) and other sexually transmitted diseases.</p><p>Undiagnosed vaginal bleeding that is suspicious for underlying conditions should be investigated.</p><p>&nbsp;</p><p>&nbsp;</p><p>Conditions which require strict medical supervision</p><p>The decision to prescribe the COC must be made using clinical judgement and in consultation with the woman. Exacerbation or first appearance of any of these conditions may indicate that use of the oral contraceptive should be discontinued:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diabetes mellitus with mild vascular disease or mild nephropathy, retinopathy or neuropathy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypertension that is adequately controlled, i.e. systolic &gt;140 to159 mm Hg or diastolic &gt; 90 to 94mmHg (see also Section 4.4 &lsquo;Reasons for stopping oral contraception immediately&rsquo;)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; porphyria</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; obesity</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; migraine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cardiovascular diseases</p><p>&nbsp;</p><p>&nbsp;</p><p>Reasons for stopping oral contraception immediately:</p><p>When stopping oral contraception non-hormonal contraception should be used to ensure contraceptive protection is maintained.</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Occurrence for the first time, or exacerbation, of migrainous headaches or unusually frequent or unusually severe headaches</p><p>&nbsp;</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sudden disturbances of vision, of hearing or other perceptual disorders</p><p>&nbsp;</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; First signs of thrombosis or blood clots (e.g. unusual pains in or swelling of the leg(s), stabbing pains on breathing or coughing for no apparent reason). Feeling of pain and tightness in the chest</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; At least four weeks before an elective major operation (e.g. abdominal, orthopaedic), any surgery to the legs, medical treatment for varicose veins or prolonged immobilisation, e.g. after accidents or surgery. Do not restart until 2 weeks after full ambulation. In case of emergency surgery, thrombotic prophylaxis is usually indicated e.g. subcutaneous heparin</p><p>&nbsp;</p><p>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Onset of jaundice, hepatitis, itching of the whole body</p><p>&nbsp;</p><p>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Significant rise in blood pressure</p><p>&nbsp;</p><p>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe upper abdominal pain or liver enlargement</p><p>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clear exacerbation of conditions known to be capable of deteriorating during oral contraception or pregnancy (see section 4.4 &lsquo;Conditions which deteriorate in pregnancy or during previous COC use&rsquo; under &#39;Other conditions&#39;)</p><p>&nbsp;</p><p>Tumours</p><p><strong>&nbsp;</strong></p><p>Numerous epidemiological studies have been reported on the risks of ovarian, endometrial, cervical and breast cancer in women using combined oral contraceptives. The evidence is clear that high dose combined oral contraceptives offer substantial protection against both</p><p>ovarian and endometrial cancer. However, it is not clear whether low dose COCs confer protective effects to the same level.</p><p>&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Breast cancer</p><p>A meta-analysis from 54 epidemiological studies reported that there is a slightly increased relative risk (RR = 1.24) of having breast cancer diagnosed in women who are currently using combined oral contraceptives (COCs). The observed pattern of increased risk may be due to an earlier diagnosis of breast cancer in COC users, the biological effects of COCs or a combination of both. The additional breast cancers diagnosed in current users of COCs or in women who have used COCs in the last ten years are more likely to be localised to the breast than those in women who never used COCs.</p><p>&nbsp;</p><p>&nbsp;</p><p>Breast cancer is rare among women under 40 years of age whether or not they take COCs. Whilst this background risk increases with age, the excess number of breast cancer diagnoses in current and recent COC users is small in relation to the overall risk of breast cancer (see bar chart).</p><p>&nbsp;</p><p>&nbsp;</p><p>The most important risk factor for breast cancer in COC users is the age women discontinue the COC; the older the age at stopping, the more breast cancers are diagnosed. Duration of use is less important and the excess risk gradually disappears during the course of the 10 years after stopping COC use such that by 10 years there appears to be no excess.</p><p>&nbsp;</p><p>&nbsp;</p><p>The possible increase in risk of breast cancer should be discussed with the user and weighed against the benefits of COCs taking into account the evidence that they offer substantial protection against the risk of developing certain other cancers (e.g. ovarian and endometrial cancer).</p><p><img src="data:image/jpeg;base64,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" alt="" width="479" height="249" vspace="0" hspace="0" border="0" style="width:479px;height:249px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cervical Cancer</p><p>The most important risk factor for cervical cancer is persistent HPV infection. Some epidemiological studies have indicated that long-term use of COCs may further contribute to this increased risk but there continues to be controversy about the extent to which this finding is attributable to confounding effects, e.g., cervical screening and sexual behaviour including use of barrier contraceptives.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Liver Cancer</p><p>In rare cases benign and, in even rarer cases, malignant liver tumours leading in isolated cases to life- threatening intra-abdominal haemorrhage have been observed after the use of hormonal substances such as those contained in Lindynette. If severe upper abdominal complaints, liver enlargement or signs of intra-abdominal haemorrhage occur, the possibility of a liver tumour should be included in the differential diagnosis.</p><p>Other conditions</p><p>The possibility cannot be ruled out that certain chronic diseases may occasionally deteriorate during the use of combined oral contraceptives.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Known hyperlipidaemia</p><p>Women with hypertriglyceridemia, or a family history thereof, may be at an increased risk of pancreatitis when using COCs.</p><p>Women with hyperlipidaemias are at an increased risk of arterial disease (see section 4.4 &lsquo;Circulatory disorders&rsquo;). However routine screening of women on COCs is not appropriate.</p><p>&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood pressure</p><p>Hypertension is a risk factor for stroke and myocardial infarction (see section 4.4 &lsquo;Arterial thromboembolic-related conditions&rsquo;). Although small increases in blood pressure have been reported in many women taking COCs, clinically relevant increases are rare. However, if sustained hypertension develops during the use of a COC, antihypertensive treatment should normally be instigated at a level of 160/100 mm Hg in uncomplicated patients or at 140/90 mm Hg in those with target organ damage, established cardiovascular disease, diabetes or with increased cardiovascular risk</p><p>&nbsp;</p><p>factors. Decisions about the continued use of the COC should be made at lower BP levels, and alternative contraception may be advised.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Conditions which deteriorate in pregnancy or during previous COC use</p><p>The following conditions have been reported to occur or deteriorate with both pregnancy and COC use. Consideration should be given to stopping Lindynette if any of the following occur during use:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; jaundice and/or pruritus related to cholestasis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; COCs may increase the risk of gallstone formation and may worsen existing disease</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; systemic lupus erythematosus</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; herpes gestationis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; otosclerosis-related hearing loss</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sickle cell anaemia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; renal dysfunction</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hereditary angioedema</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; any other condition an individual woman has experienced worsening of during pregnancy or previous use of COCs.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Disturbances of liver function</p><p>Acute or chronic disturbances of liver function may necessitate the discontinuation of COC use until markers of liver function return to normal.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diabetes (without vascular involvement)</p><p>Insulin-dependent diabetics without vascular disease can use COCs. However it should be remembered that all diabetics are at an increased risk of arterial disease and this should be considered when prescribing COCs. Diabetics with existing vascular disease are contraindicated from using COCs (see section 4.3 Contraindications).</p><p>Although COCs may have an effect on peripheral insulin resistance and glucose tolerance, there is no evidence for a need to alter the therapeutic regimen in diabetics using low-dose COCs (containing &lt; 0.05 mg ethinylestradiol). However, diabetic women should be carefully observed while taking COCs.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Psychiatric Disorders</p><p>Depressed mood and depression are well-known undesirable effects of hormonal contraceptive use (see section 4.8). Depression can be serious and is a well-known risk factor for suicidal behaviour and suicide. Women should be advised to contact their physician in case of mood changes and depressive symptoms, including shortly after initiating the treatment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chloasma</p><p>Chloasma may occasionally occur, especially in women with a history of chloasma gravidarum. Women with a tendency to chloasma should avoid exposure to the sun or ultraviolet radiation whilst taking COCs.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Menstrual Changes</p><p><!--[if gte vml 1]><v:shape
 id="Graphic_x0020_6" o:spid="_x0000_s1026" style='position:absolute;left:0;
 text-align:left;margin-left:69.5pt;margin-top:23.8pt;width:456.45pt;height:23.9pt;
 z-index:-16096256;visibility:visible;mso-wrap-style:square;
 mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:page;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;v-text-anchor:top' coordsize="5796915,303530"
 o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" path="m5796660,l,,,303276r5796660,l5796660,xe" stroked="f">
 <v:path arrowok="t"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="609" height="31" src="file:///C:/Users/101623/AppData/Local/Temp/msohtmlclip1/01/clip_image005.gif" />Reduction of menstrual flow: This is not abnormal and it is to be expected in some patients. Indeed, it may be beneficial where heavy periods were previously experienced.</p><p>&nbsp;</p><p>Missed menstruation: Occasionally, withdrawal bleeding may not occur at all. If the tablets have been taken correctly, pregnancy is very unlikely. If withdrawal bleeding fails to occur at the end of a second pack, the possibility of pregnancy must be ruled out before resuming with the next pack.</p><p>Intermenstrual bleeding: Irregular bleeding (spotting or breakthrough bleeding) may occur especially during the first months of use. Therefore, the evaluation of any irregular bleeding is only meaningful after an adaptation interval of about three cycles. If bleeding irregularities persist or occur after previously regular cycles, then non-hormonal causes should be considered and adequate diagnostic measures are indicated to exclude malignancy or pregnancy. This may include curettage.</p><p>Some women may experience amenorrhoea or oligomenorrhoea after discontinuation of oral contraceptives, especially when these conditions existed prior to use. Women should be informed of this possibility.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lactose, Sucrose and Sodium Intolerance</p><p>Each tablet of this medicinal product contains 37.43 mg lactose and 19.660 mg sucrose per tablet. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, fructose intolerance or glucose-galactose malabsorption or sucrase-isomaltase should not take this medicine.</p><p>This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium- free&rsquo;.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ALT elevations</p><p>During clinical trials with patients treated for hepatitis C virus infections (HCV) with the medicinal products containing ombitasvir / paritaprevir / ritonavir and dasabuvir with or</p><p>without ribavirin, transaminase (ALT) elevations higher than 5 times the upper limit of normal (ULN) occurred significantly more frequently in women using ethinylestradiol- containing medications such as combined hormonal contraceptives (CHCs). Additionally, also in patients treated with glecaprevir / pibrentasvir, ALT elevations were observed in women using ethinylestradiol-containing medications such as CHCs (see section 4.3 and 4.5).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Note</u></em>: The prescribing information of concomitant medications should be consulted to identify potential interactions.</p><p>&nbsp;</p><p><u>Enzyme inducers</u></p><p>Interactions can occur with drugs that induce microsomal enzymes (especially cytochrome P450 3A4) which can result in increased clearance of sex hormones, and which may lead to breakthrough bleeding and/or contraceptive failure.</p><p>Enzyme induction can already be observed after a few days of treatment. Maximal enzyme induction is generally seen within a few weeks. After the cessation of drug therapy enzyme induction may be sustained for about 4 weeks.</p><p>Women on short term treatment with any of these drugs should temporarily use a barrier method in addition to the COC or choose another method of contraception. The barrier method should be used during the time of concomitant drug administration and for 28 days after their discontinuation. If the period during which the barrier method is used runs beyond the end of a pack, the next pack should be started without a break. In this situation, a withdrawal bleed should not be expected until the end of the second pack. If the patient does not have a withdrawal bleed during the tablet-free interval following the end of the second pack, the possibility of pregnancy must be ruled out before resuming with the next pack.</p><p>For women receiving long-term therapy with enzyme inducers, another method of contraception should be used.</p><p>&nbsp;</p><p><u>The following have been shown to have clinically important interactions with COCs:</u> <em>Anticonvulsants</em>: barbiturates (including phenobarbitone), primidone, phenytoin, carbamazepine, oxcarbazepine, topiramate.</p><p><em>Antibiotics/antifungals</em>: griseofulvin, rifampacin.</p><p><em>Herbal remedies</em>: St John&rsquo;s wort (Hypericum perforatum) Antiretroviral agents: ritonavir, nelfinavir, nevirapine.</p><p><em><u>Note</u></em>: There are other antiretroviral agents that may increase plasma concentration of sex hormones.</p><p><em>Substances decreasing the clearance of COCs (enzyme inhibitors)</em></p><p>Strong and moderate CYP3A4 inhibitors such as azole antifungals (e.g. itraconazole, voriconazole, fluconazole) and macrolides (e.g. erythromycin) can increase plasma concentrations of the oestrogen or the progestin or both.</p><p>Etoricoxib doses of 60 to 120 mg/day have been shown to increase plasma concentrations of ethinylestradiol 1.4 to 1.6-fold, respectively when taken concomitantly with a combined hormonal contraceptive containing 0.035 mg ethinylestradiol.</p><p><u>Effects on other drugs</u></p><p>Oral contraceptives may affect the metabolism of certain other drugs. Accordingly, plasma and tissue concentrations may either increase (e.g. cyclosporin, tizanidine, theophylline) or decrease (e.g. lamotrigine).</p><p><u>Pharmacodynamic interactions</u></p><p>Concomitant use with the medicinal products containing ombitasvir / paritaprevir / ritonavir and dasabuvir, with or without ribavirin, or glecaprevir / pibrentasvir may increase the risk of ALT elevations (see sections 4.3 and 4.4).</p><p>Therefore, Lindynette-users must switch to an alternative method of contraception (e.g., progestagen- only contraception or non-hormonal methods) prior to starting therapy with this combination drug regimen. Lindynette can be restarted 2 weeks following completion of treatment with this combination drug regimen.</p><p><u>Other forms of interactions</u></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Laboratory tests</p><p>The use of oral contraceptives may influence the results of certain laboratory tests including biochemical parameters of liver, thyroid, adrenal and renal function, plasma levels of carrier proteins and lipid/lipoprotein fractions, parameters of carbohydrate metabolism and parameters of coagulation and fibrinolysis. Laboratory staff should therefore be informed about oral contraceptive use when laboratory tests are requested.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lindynette is not indicated during pregnancy. If pregnancy occurs during treatment with Lindynette, further intake must be stopped. However, extensive epidemiological studies have revealed neither an</p><p>increased risk of birth defects in children born to women who used COCs prior to pregnancy, nor a teratogenic effect when COCs were taken inadvertently during early pregnancy.</p><p>The increased risk of VTE during the postpartum period should be considered when re- starting Lindynette (see section 4.2 and 4.4).</p><p>The use of Lindynette during lactation may lead to a reduction in the volume of milk produced and to a change in its composition. Minute amounts of the active substances are excreted with the milk.</p><p>These amounts may affect the child particularly in the first 6 weeks post-partum. Mothers who are breast-feeding may be advised instead to use another method of contraception.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lindynette has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The most commonly reported adverse reactions with Lindynette are nausea, abdominal pain, increased</p><p>&nbsp;</p><p>weight, headache, depressed mood, altered mood, breast pain, breast tenderness. They occur in &ge;1% of users.</p><p>&nbsp;</p><p>Serious adverse reactions are arterial and venous thromboembolism.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Adverse events reported in clinical trials</strong></p></td><td style="vertical-align:top"><p><strong>Adverse events</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Class</strong></p></td><td style="vertical-align:top"><p><strong>Common (&sup3; 1/100)</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon (&sup3; 1/1000,</strong></p><p><strong>&lt;1/100)</strong></p></td><td style="vertical-align:top"><p><strong>Rare (&lt; 1/1000)</strong></p></td><td style="vertical-align:top"><p><strong>reported post marketing</strong></p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Contact lens intolerance</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Nausea, abdominal pain</p></td><td style="vertical-align:top"><p>Vomiting, diarrhea</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Ulcerative colitis</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hypersensitivity</p></td><td style="vertical-align:top"><p>Exacerbation of</p><p>hereditary angioedema</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Weight increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Weight decreased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Fluid retention</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>headache</p></td><td style="vertical-align:top"><p>Migrane</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vascular system</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Venous thromboembolism (VTE),</p><p>Arterial thromboembolism (ATE)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Liver function disturbances</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Depressed mood, Mood altered</p></td><td style="vertical-align:top"><p>Libido decreased</p></td><td style="vertical-align:top"><p>Libido increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>Breast pain, breast tenderness</p></td><td style="vertical-align:top"><p>Breast hypertrophy</p></td><td style="vertical-align:top"><p>Vaginal discharge, Breast discharge</p></td><td style="vertical-align:top"><p>Reduced menstrual flow, spotting, breakthrough bleeding and missed withdrawal bleeding, post pill amenorrhoea</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rash, urticaria</p></td><td style="vertical-align:top"><p>Erythema nodosum, erythema multiforme</p></td><td style="vertical-align:top"><p>chloasma</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>Description of selected adverse reactions</p><p>An increased risk of arterial and venous thrombotic and thrombo-embolic events, including myocardial infarction, stroke, transient ischemic attacks, venous thrombosis and pulmonary embolism has been observed in women using CHCs, which are discussed in more detail in section 4.4.</p><p>The following serious adverse events have been reported in women using COCs, which are discussed in section 4.4 &#39;Special warnings and precautions for use&#39;:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Venous thromboembolic disorders</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Arterial thromboembolic disorders</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Strokes (e.g. transient ischemic attack, ischemic stroke, haemorrhagic stroke)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypertension</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypertriglyceridemia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Liver tumours (benign and malignant)</p><p>&nbsp;</p><p>&nbsp;</p><p>The frequency of diagnosis of breast cancer is very slightly increased among COC users. As breast cancer is rare in women under 40 years of age the excess number is small in relation to the overall risk of breast cancer. Causation with COC use is unknown. For further information, see sections 4.3 &lsquo;Contraindications&rsquo; and 4.4 &lsquo;Special warnings and precautions for use&rsquo;.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Conditions reported to deteriorate with pregnancy or previous COC use</u></p><p>&nbsp;</p><p>&nbsp;</p><p>Jaundice and/or pruritus related to cholestasis; gallstone formation; systemic lupus erythematosus; herpes gestationis; otosclerosis-related hearing loss; Crohn&rsquo;s disease, sickle cell anaemia; renal dysfunction; hereditary angioedema; porphyria; cervical cancer.</p><p>&nbsp;</p><p>&nbsp;</p><p>Changes in glucose tolerance or effect on peripheral insulin resistance have been reported in women using COCs (see section 4.4).</p><p>&nbsp;</p><p>&nbsp;</p><p>Reporting of suspected adverse reactions</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via</p><p>&nbsp;</p><p>&nbsp;</p><p>To report any side effect(s):</p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="Textbox_x0020_7" o:spid="_x0000_s1026" type="#_x0000_t202"
  style='position:absolute;margin-left:79.45pt;margin-top:13.35pt;width:436.15pt;
  height:77.65pt;z-index:-15728128;visibility:visible;mso-wrap-style:square;
  mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
  mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
  mso-position-horizontal-relative:page;mso-position-vertical:absolute;
  mso-position-vertical-relative:text;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" strokeweight=".33861mm">
  <v:path arrowok="t"/>
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-top:.05pt;margin-right:0in;margin-bottom:
     0in;margin-left:0in;margin-bottom:.0001pt'>The<span style='letter-spacing:
     -.3pt'> </span>National<span style='letter-spacing:-.25pt'> </span>Pharmacovigilance<span
     style='letter-spacing:-.3pt'> </span>Centre<span style='letter-spacing:
     -.35pt'> </span><span style='letter-spacing:-.1pt'>(NPC).</span><o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:2.25pt;margin-right:0in;margin-bottom:
     0in;margin-left:.5in;margin-bottom:.0001pt;line-height:13.1pt;mso-line-height-rule:
     exactly'><span style='font-family:"Courier New";mso-hansi-font-family:
     "Times New Roman";mso-bidi-font-family:"Times New Roman"'>o<span
     style='letter-spacing:.8pt'> </span></span>Phone<span style='letter-spacing:
     -.15pt'> </span>number:<span style='letter-spacing:-.1pt'> 19999</span><o:p></o:p></p>
     <p class=MsoBodyText style='margin-left:50.35pt;text-indent:-14.35pt;
     line-height:12.75pt;mso-line-height-rule:exactly;mso-list:l1 level1 lfo1;
     tab-stops:50.35pt'><![if !supportLists]><span style='font-family:"Courier New";
     mso-fareast-font-family:"Courier New"'><span style='mso-list:Ignore'>o<span
     style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
     dir=LTR></span>E-mail:<span style='letter-spacing:-.15pt'> </span><a
     href="mailto:npc.drug@sfda.gov.sa"><span style='color:windowtext;
     letter-spacing:-.1pt;text-decoration:none;text-underline:none'>npc.drug@sfda.gov.sa</span></a><o:p></o:p></p>
     <p class=MsoBodyText style='margin-left:50.35pt;text-indent:-14.35pt;
     line-height:13.15pt;mso-line-height-rule:exactly;mso-list:l1 level1 lfo1;
     tab-stops:50.35pt'><![if !supportLists]><span style='font-family:"Courier New";
     mso-fareast-font-family:"Courier New"'><span style='mso-list:Ignore'>o<span
     style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
     dir=LTR></span>Website:<span style='letter-spacing:-.1pt'> </span><a
     href="http://www.sfda.gov.sa/npc"><span style='color:windowtext;
     letter-spacing:-.1pt;text-decoration:none;text-underline:none'>www.sfda.gov.sa/npc</span></a><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><p>&nbsp;</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>The National Pharmacovigilance Centre (NPC).</p><p>o Phone number: 19999</p><p>o&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>o&nbsp; Website: www.sfda.gov.sa/npc</p><p>&middot;&nbsp;&nbsp; Other GCC Slates:</p><p>Please contact the relevant competent authority.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms of oral contraceptive overdose in adults and children may include nausea, vomiting, breast tenderness, dizziness, abdominal pain, drowsiness/fatigue. Withdrawal bleeding may occur in females. There is no specific antidote, and further treatment of overdose, if necessary, is directed to the symptoms.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Sex hormones and modulators of the genital system; Progestogens and estrogens, fixed combinations; ATC code: G03AA10.</p><p>The contraceptive effect of contraceptive pills rests on the interaction of various factors, the most important of which are inhibition of ovulation and changes in cervical secretions. Besides protection from pregnancy, contraceptive pills have several positive qualities which, when considered against their negative points, are useful to know when one is making a decision about the prevention of pregnancy. The menstrual cycle becomes more regular, menstruation is often less painful, and bleeding is not as heavy. The latter can contribute to reducing the occurrence of iron deficiency. In addition to this, it has been demonstrated that high-dosage contraceptive pills (50 &mu;g ethinylestradiol) lower the risk of fibrocystic tumours of the breast, ovarian cysts, adnexitis, ectopic pregnancy, as well as endometrial and ovarian cancer. It has not yet been confirmed whether this also applies to low- dosage contraceptive pills.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Gestodene</p><p><strong><u>Absorption</u></strong></p><p>Gestodene, when taken orally, is absorbed quickly and completely. Following a single dose the maximum serum concentration of 4 ng/ml is reached in approximately one hour. Bioavailability is approximately</p><p>.99%</p><p><strong><u>Distribution</u></strong></p><p>Gestodene is bound to serum albumin and to sex hormone binding globulin (SHBG). Only 1-2% of the total amount of gestodene in serum is found as free steroid, while 50-70% is specifically bound to SHBG.</p><p>The ethinylestradiol-induced increase in SHBG influences the distribution of serum proteins, which causes an increase of the SHBG-bound fraction, and a decrease of the albumin-bound fraction. The</p><p>.apparent distribution volume of gestodene is 0.7 l/kg</p><p>&nbsp;</p><p><strong><u>Biotransformation</u></strong></p><p>Gestodene is metabolised completely via the known pathways of steroid metabolism. The metabolic clearance rate from serum is 0.8 ml/min/kg. No interaction occurs when gestodene is</p><p>.taken together with ethinylestradiol</p><p>&nbsp;</p><p><strong><u>Elimination</u></strong></p><p>&ndash; Serum level of gestodene is reduced at 2 rates. The last rate is characterised by a half-life of 12 hours. Gestodene is not excreted. Its metabolites are excreted in urine and in bile at a ratio 15</p><p>.of 6:4. The half-life of metabolite excretion is approximately 1 day</p><p>&nbsp;</p><p><strong><u>Steady-state</u></strong></p><p>Pharmacokinetics of gestodene is influenced by the levels of SHBG in serum, which increase to triple values with ethinylestradiol. Upon daily intake, the level of gestodene in serum</p><p>increases till approximately four times the single dose value, and reaches steady-state within the</p><p>.second half of the treatment cycle</p><p>&nbsp;</p><p>Ethinylestradiol</p><p><strong><u>Absorption</u></strong></p><p>Ethinylestradiol, taken orally, is absorbed quickly and completely. Maximal serum</p><p>,concentration of about 80 pg/ml is reached within 1-2 hours. Complete bioavailability</p><p>.resulting from pre-systemic conjugation and first-pass metabolism, is approximately 60%</p><p><strong><u>Distribution</u></strong></p><p>Ethinylestradiol is predominantly bound non-specifically to albumin (approx. 98.5), and causes increase in serum concentration of SHBG. The apparent distribution volume is found to be</p><p>.approximately 5 l/kg</p><p><strong><u>Biotransformation</u></strong></p><p>,Ethinylestradiol undergoes pre-systemic conjugation both in the mucosa of the small intestine and in the liver. Ethinylestradiol is primarily metabolised by aromatic hydroxylation, but many different hydroxylated and methylated metabolites are formed, and found as free metabolites and as glucuronide and sulphate conjugates. The metabolic clearance rate is approximately 5</p><p>.ml/min/kg</p><p><strong><u>Elimination</u></strong></p><p>.Serum level of ethinylestradiol is reduced at 2 rates, the last one with a half-life of 24 hours Ethinylestradiol is not excreted, but its metabolites are excreted in urine and in bile at a ratio</p><p>.of 4:6. The half-life of metabolite excretion is approximately 1 day</p><p><strong><u>Steady-state</u></strong></p><p>Steady-state occurs after 3-4 days, and the serum levels of ethinylestradiol are 30-40% higher than at single</p><p>..dose</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The combination of ethinylestradiol and gestodene, like other contraceptive steroids, is associated with an increased incidence of neoplastic nodules in the rat liver, the relevance of which to man is unknown. Malignant liver tumours have been reported on rare occasions in long-term users of oral contraceptives.</p><p>There are no other preclinical safety data which could be of relevance to the prescriber and which are not already included in other relevant sections of the SPC.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium calcium edetate, Magnesium stearate, Silica colloidal anhydrous, Povidone, Maize starch, Lactose monohydrate, &ldquo;Quinoline&rdquo; Yellow (E 104), Titanium dioxide, Macrogol 6000, Talc, Calcium carbonate, Sucrose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C. Store in the original package in order to protect from light and moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>21 coated tablets in PVC/PVDC//Al blister, in folded carton.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>Note: X (Single cross)</p><p>Availability: <strong>group II.</strong></p><p>Medicinal product subject to medical prescription (V).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Marketing Authorisation Holder
AJA Pharmaceutical Industries Company, Ltd. Hail Industrial City MODON, Street No 32 PO Box 6979 , Hail 55414
Kingdom of Saudi Arabia

Manufacture:
Gedeon Richter Plc. H-1103 Budapest Gyömrői út 19-21. Hungary


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                28/11/2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>